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Pathogens such as human papillomaviruses (HPVs) have co-evolved with their hosts and 
form a molecular basis for common diseases. Persistent infection with the “high-risk” HPV type 
16 (HPV16) is a potent cause of anogenital and oropharyngeal cancers. Taxonomic HPV16 sub-
lineages, based on geographic origin of discovery, are noteworthy due to their variable 
tumourigenicity. In this dissertation, I present basic research and the resulting biotechnologies we 
developed, improved, and utilized to study their fascinating pathogen-host relationship with human 
stratified epithelia. A small number of variations in the E6 gene of HPV16, found in the D2 and 
D3 sub-lineages, lead to increased tumourigenic risk compared to the prototype A1 sub-lineage. 
Using an organotypic human epithelial model (or in vitro organoid) we recapitulated the viral life 
cycle and used “-omics” analyses to assess viral and host molecular differences due to sub-lineage 
variation. Sub-lineage variants of E6 were associated with host genome instability and viral 
integration into host DNA. Following these initial findings, I provide perspective on epithelial 
organoids, namely that the trade-off between model complexity and feasibility should be sensibly 
considered based on its utility for answering the biological research question at hand. Model 
applications and improvements are presented, including time-series epithelial stratification 
measurements, strategies for introducing full-length sub-lineage HPV16 genomes into host 
keratinocytes, and experiments to study innate immune evasion. These wet-lab works are 
accompanied by software to aid biologists in analyzing sequencing data. As well, we present 
current work using The Cancer Genome Atlas to test the association between HPV16 sub-lineage 
and integration. Overall, this interdisciplinary and interconnected collection has significance for 
basic researchers, providing insight on how a small number of natural viral variations can lead to 
increased tumourigenic risk, as well as for experimentalists to gain insight on organoid modelling 
and novel bioinformatics tools. More broadly, characterizing these molecular interactions between 
pathogen and host enables us to form a basis for diagnosis, treatment, and ultimately prevention 
of disease. Future research should aim to closely integrate biological and computational sciences 
for improving experimental approaches and our ability to make meaningful biological 
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CHAPTER 1 – INTRODUCTION 
1.1 – Literature Review 
Viruses and their hosts have complex, albeit, fascinating relationships: “two-stepping” 
together through evolutionary time [Meyerson and Sawyer, 2011]. These molecular interactions 
are influenced by a mixture of viral, host, as well as environmental factors, and can manifest in 
host disease, including cancers [Chang et al., 2017]. While seven groups of human oncoviruses 
are established (i.e., human papillomavirus, hepatitis B and C viruses, human T-lymphotropic 
virus-1, Kaposi sarcoma herpesvirus, Epstein-Barr virus, and Merkel cell polyomavirus) [Chang 
et al., 2017], human papillomaviruses (HPVs) are the most common pathogens associated with 
human malignancies [zur Hausen, 1996; 2002]. HPVs are double-stranded DNA viruses, a subset 
of which, the so-called “high-risk” HPVs, cause 5.2% of human cancers [Parkin and Bray, 2006]. 
Although 500+ types of human and non-human PVs exist [Van Doorslaer et al., 2013; 2017a; 
2017b], HPV type 16 (a member of the viral species Alphapapillomavirus 9) is the most prevalent 
of the high-risk human types, causing anogenital cancers (e.g., of the cervix) as well as 
oropharyngeal cancers as a result of persistent infection. Its potent tumourigenicity is reflective of 
the activities of virally encoded oncoproteins, primarily E6 [reviewed by Vande Pol et al., 2013] 
and E7 [reviewed by Roman and Münger, 2013]. However, the role of the entire viral genome and 
the viral life cycle needs to be considered when studying viral tumourigenesis due to cis-acting 
viral proteins (such as E2, which is involved in regulating E6/E7 expression) as well as the 
complexity of viral-host interactions (such as the emerging understanding of an oncogenic role for 
E5) [Doorbar et al., 2012]. A useful unifying framework for studying the molecular and cellular 
basis of how cancers form, named the “hallmarks of cancer” [Figure 1.1], is described by Hanahan 
and Weinberg [2000; 2011] and were further expanded by Mesri et al. [2014] to oncoviruses. 
Intratypic variants (or sub-lineages) of HPV16 have co-evolved with human populations 
and differ in their persistence and frequency of detection in pre-cancers and cancers [Burk et al., 
2013]. The tumourigenic differences of these variants have been ascribed, at least partially, to 
genomic variation within the E6 oncogene (but also include interaction effects with host genome 
variability [Togtema et al., 2015]). The Asian-American (AA, also known as the D2 and D3 sub-
lineage) and European Prototype (EP, also known as the A1 sub-lineage) are common genomic 
variants of HPV16 with their E6 genes differing by only six single-nucleotide polymorphisms 
(SNPs), three of which are non-synonymous leading to the 151-residue AAE6 protein differing by 
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three amino-acids: Q14H, H78Y, and L83V [Cornet et al., 2012]. Epidemiological studies revealed 
that coding changes in E6 have differential tumourigenic risk [Zehbe et al., 1998a; 1998b; 2001; 
Grodzki et al., 2006] and that AA is a higher risk factor for dysplasia as well as earlier onset 
invasive tumours than EP [Xi et al., 1997; 2007; Villa et al., 2000; Berumen et al., 2001; Schiffman 
et al., 2010; Freitas et al., 2014]. As well, AAE6 alone has a greater transforming, migratory, and 
invasive potential than EPE6 when retrovirally transduced into primary human keratinocytes 
during recent long-term in vitro immortalization studies [Zehbe et al., 2009; Richard et al., 2010; 
Niccoli et al., 2012; Togtema et al., 2015], as well as altered cellular energetics [Cuninghame et 
al., 2017], consistent with the hypothesis that coding changes in E6 contribute to differences in 
cancer risk. Protein-based binding experiments are being conducted to determine unique properties 
and cellular partners of HPV16 E6 variant proteins [Mehran Masoom, unpublished observations]. 
Our lab is also investigating anti-E6 therapeutics, including monoclonal antibodies introduced to 
target cells via sonoporation [Togtema et al., 2012], RNA-interference using small-interfering 
RNA (siRNA) [Togtema et al., 2018b], and camelid-derived single-domain antibodies [Togtema 
et al., 2018a]. 
In our previous investigation of these two common HPV16 E6 variants we demonstrated 
that AAE6 drives tumourigenesis in an early infection scenario (using 3D epithelial cultures) by 
increasing cellular proliferation, disrupting differentiation and apoptosis, decreasing innate 
immune gene expression, and promoting immortalization [Jackson et al., 2014]. The differences 
in host epithelia were reflective of increased oncogene expression in AAE6 cultures (E6 and E7) 
and loss of productive life cycle (decreased E2, E1^E4, and L2), both suspected to be a result of 
integration of the AAE6 viral DNA into the host genome [Jackson et al., 2014]. To further address 
this hypothesis, and characterize the molecular pathways involved, it became essential to use high-
throughput “-omics” techniques coupled with bioinformatics. Additional chapter-specific 
literature review addressing these topics is provided throughout the dissertation [2.2 – 
Background, 3A.2 – Introduction, 4A.2 – Introduction, and 4B.2 – Introduction] to 











Figure 1.1 – Hallmarks of cancer. Hanahan and Weinberg [2000; 2011] describe ten useful traits 
for characterizing the abilities that cancer cells gain during tumourigenesis. These hallmarks and 
enabling characteristics can be used as a unifying framework for studying cancers, including those 
caused by pathogens [Mesri et al., 2014]. This figure is based on Figure 6 from Hanahan and 





1.2 – Research Rationale, Question, Hypothesis, and Objectives 
While a considerable amount of information has been gathered in the past few decades 
about the tumourigenic relationship between HPV16 and human keratinocytes, much of the 
fundamental work has been performed in classical monolayer experiments (preventing a full viral 
life cycle from occurring) and using single genes (preventing a full viral life cycle, but also missing 
the interactions due to the full viral genome being present). As well, given that a low proportion 
of HPV16 infections persist to invasive cancer [Stanley, 2012], factors affecting persistence and 
progression to carcinogenesis (especially those associated with viral variation), deserve scrutiny 
in biologically relevant experimental models. To understand these factors, the concept of a 
“pathogenic lifestyle” from Dr. Stanley Falkow comes to mind: “Falkow came to think of the 
‘pathogenic lifestyle’ as being not about causing disease, but rather about subtly manipulating a 
host. He became best friends with his prey” [Amieva, 2018]. Given the subtly of interactions, 
where pathogens have adapted mechanisms to subvert cellular machinery and processes, the 
comprehensive study of these pathogen-host relationships requires experimental approaches that 
provide a realistic host environment (epithelial organoids), full-length “competent” viral genomes, 
and sensitive analytics (“-omics” techniques and tools such as next-generation sequencing and 
bioinformatics). Overall, my goal was to fill these gaps and share with the scientific community 
how small genomic variations in pathogens, such as that between HPV16 sub-lineages, cause 
significant changes in host mechanisms manifesting in disease. In other words, to answering the 
question: why is the Asian-American (AA, D2/D3 sub-lineage) variant of HPV16 more 
tumourigenic than the European Prototype (EP, A1 sub-lineage) variant? We hypothesize that 
virus-host interactions differ between HPV16 sub-lineages (A1 vs D2/D3, otherwise known as 
variants, EP vs AA) and that specifically D2/D3 promotes tumourigenic molecular pathways (e.g., 
genomic instability) while suppressing anti-tumourigenic molecular pathways (e.g., innate 
immune response) compared to A1. To address these hypotheses, basic (fundamental) research 
was conducted on the pathogen-host relationship of HPV16 sub-lineages. Whilst doing so, we 
developed, enhanced, and utilized novel biotechnologies, including: three-dimensional 
organotypic human epithelia (in vitro organoids) capable of hosting a productive and reproducible 
viral life cycle, and bioinformatics tools and “-omics” analyses for pathogen-host relationships. 
These objectives were accomplished via an experimental scheme using HPV16 variant genomes, 









Figure 1.2 – Experimental scheme. HPV16 variant genomes were introduced to human epithelial 
organoids permitting an active viral life cycle alongside host keratinocyte differentiation. 
Molecular analyses were performed on DNA and RNA, characterizing both viral and human 
sequences, including viral-human integrations and fusion transcripts. This figure has been adapted 





1.3 – Original Scientific Contributions 
This dissertation is structured as a hybrid thesis [Figure 1.3], with chapters including 
published scientific contributions as well as unpublished complementary material. This original 
work included interdisciplinary collaboration throughout the duration of my doctoral studies. 
Given my prior work on papillomaviruses it is essential that I first demarcate the continuum of my 
contributions. Prior to my current degree studies, four co-authored articles were published 
[DeCarlo et al., 2012; Togtema et al., 2012; Jackson et al., 2013; Pichardo et al., 2013]. Since 
starting doctoral work, an additional eleven co-authored articles were published (or accepted for 
publication), four of which (underlined and bolded) are included within this dissertation 
[Cuninghame et al., 2014; 2017; Jackson et al., 2014; 2016; 2019; Togtema et al., 2015; 2018b; 
Zehbe et al., 2016a; Villa et al., 2018; Gibb et al., 2019; Murall et al., 2019]. These contributions 
span basic science, therapeutics, as well as community-based screening and prevention studies. 
Initial findings on viral-host integration due to HPV16 sub-lineage are presented in 
CHAPTER 2 in the form of a first-author research article [Jackson et al., 2016]. This chapter lays 
the foundation for all other chapters, as it includes both biological and computational aspects which 
are each further expanded. CHAPTER 3A, CHAPTER 3B, and CHAPTER 3C are based on the 
epithelial organoid model. Perspectives on using epithelial organoids for studying the viral life 
cycle of human papillomaviruses are discussed in CHAPTER 3A, as a first-author commentary 
article [Jackson et al., 2019]. Following these, epithelial organoids are applied in CHAPTER 3B 
to study stratification dynamics, informing parameters of ecologically-based in silico 
mathematical models of infection which includes excerpts from a co-authored research article 
[Murall et al., 2019]. Additional enhancements to the organoid model are presented in CHAPTER 
3C, including recent progress on full-length HPV16 variant genomes, transfection strategies into 
host keratinocytes of different anatomical origin, and studying innate immunity. CHAPTER 4A 
and CHAPTER 4B focus on bioinformatics and analysis of next-generation sequencing data for 
papillomaviral sequences. In CHAPTER 4A, the development of the Pathogen-Host Analysis 
Tool (PHAT) software is presented as a co-first-author article [Gibb et al., 2019]. Current progress 
on analyses of The Cancer Genome Atlas (TCGA) datasets, with tumours containing HPV16, are 
described in CHAPTER 4B. CHAPTER 5 concludes the dissertation, highlighting its primary 
significance for basic researchers and experimentalists, as well as the broad impact of studying 





Figure 1.3 – Dissertation layout. The dissertation contains five main-body chapters: an 
introduction (Chapter 1: literature review, research rationale and objectives), initial findings 
(Chapter 2: a first authored research article [Jackson et al., 2016]), three interconnected epithelial 
organoid model chapters (Chapter 3A: a first authored perspective article [Jackson et al., 2019]; 
Chapter 3B: an excerpt from a collaborative research article [Murall et al., 2019]; and Chapter 3C: 
unpublished progress on enhancing the model’s biological relevance), two interconnected 
bioinformatics chapters (Chapter 4A: a co-first authored software article [Gibb et al., 2019]; and 
Chapter 4B: unpublished progress on analyzing The Cancer Genome Atlas data), as well as 




CHAPTER 2 – VIRAL-HOST INTEGRATION DUE TO SUB-LINEAGE 
This chapter represents initial findings from my doctoral work and was published as a 
research article in BMC Genomics on 2 Nov 2016 in volume 17, as article 851 (DOI: 
10.1186/s12864-016-3203-3) [Jackson et al., 2016]. It has been adapted with permission for re-
use within this dissertation, as it was published under a CC-BY license and the authors retain the 
original copyright. 
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2.1 – Abstract 
2.1.1 – Background 
Human papillomaviruses (HPVs) are a worldwide burden as they are a widespread group 
of tumour viruses in humans. Having a tropism for mucosal tissues, high-risk HPVs are detected 
in nearly all cervical cancers. HPV16 is the most common high-risk type but not all women 
infected with high-risk HPV develop a malignant tumour. Likely relevant, HPV genomes are 
polymorphic and some HPV16 single nucleotide polymorphisms (SNPs) are under evolutionary 
constraint instigating variable oncogenicity and immunogenicity in the infected host. 
 
2.1.2 – Results 
To investigate the tumourigenicity of two common HPV16 variants, we used our recently 
developed, three-dimensional organotypic model reminiscent of the natural HPV infectious cycle 
and conducted various “omics” and bioinformatics approaches. Based on epidemiological studies 
we chose to examine the HPV16 Asian-American (AA) and HPV16 European Prototype (EP) 
variants. They differ by three non-synonymous SNPs in the transforming and virus-encoded E6 
oncogene where AAE6 is classified as a high- and EPE6 as a low-risk variant. Remarkably, the 
high-risk AAE6 variant genome integrated into the host DNA, while the low-risk EPE6 variant 
genome remained episomal as evidenced by highly sensitive Capt-HPV sequencing. RNA-seq 
experiments showed that the truncated form of AAE6, integrated in chromosome 5q32, produced 
a local gene over-expression and a large variety of viral-human fusion transcripts, including long 
distance spliced transcripts. In addition, differential enrichment of host cell pathways was observed 
between both HPV16 E6 variant-containing epithelia. Finally, in the high-risk variant, we detected 
a molecular signature of host chromosomal instability, a common property of cancer cells. 
 
2.1.3 – Conclusions 
We show how naturally occurring SNPs in the HPV16 E6 oncogene cause significant 
changes in the outcome of HPV infections and subsequent viral and host transcriptome alterations 
prone to drive carcinogenesis. Host genome instability is closely linked to viral integration into 
the host genome of HPV-infected cells, which is a key phenomenon for malignant cellular 
transformation and the reason for uncontrolled E6 oncogene expression. In particular, the finding 
of variant-specific integration potential represents a new paradigm in HPV variant biology. 
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2.2 – Background 
Approximately 20% of human cancers are caused by infectious agents [Bouvard et al., 
2009], including >500,000 patients diagnosed annually with human papillomavirus (HPV) 
associated cancers. Oncogenic HPV, denoted as “high-risk”, is the primary risk factor for cervical 
cancer due to its exclusive tropism for mucosal tissues [zur Hausen, 1996; 2002]. Upon persistent 
infections of the cervical mucosa, oncogenic HPVs can cause progression from low- to high-grade 
cervical intraepithelial neoplasias that, without ablative treatment, may develop into invasive 
carcinomas. At the molecular level HPV is a double-stranded DNA virus and, to date, the 
sequences of over 200 types have been described [Kocjan et al., 2015]. The ~8 kbp genome of 
HPV contains 8 functional open reading frames (ORFs) that encode 5 early gene products (E1, E2, 
E5, E6 and E7) and 3 late gene products (E4, L1 and L2). While E1 and E2 are involved in DNA 
replication and transcriptional regulation of the viral genome [Doorbar et al., 2012], HPV’s potent 
tumourigenicity is primarily due to E6 [Vande Pol and Klingelhutz, 2013], E7 [Roman and 
Münger, 2013], and E5 [Maufort et al., 2007]. L1 and L2 are structural proteins that self-assemble 
to form icosahedral capsids [Conway and Meyers, 2009], while the fused product of ORFs E1 and 
E4 (E1^E4) is most abundant in the productive viral life cycle, coinciding with the onset of viral 
DNA amplification [Middleton et al., 2003]. 
 Among the HPV types, HPV16 (a member of species Alphapapillomavirus 9) is the most 
prevalent in cervical cancers. Intriguingly, and perhaps related to its prevalence, the HPV16 
genome is polymorphic. Evolutionary analyses have revealed that the worldwide diversity of 
HPV16 genomes evolved for over 200,000 years [Bernard, 2005], leading to five phylogenetic 
branches representing isolates from Africa, Europe, Asia and the Americas [Yamada et al., 1997]. 
Furthermore, each branch can be further dissected into intratypic single nucleotide polymorphisms 
(SNPs) or variants differing in their host persistence and frequency of detection in human pre-
cancers and cancers (reviewed in [Burk et al., 2013]). The tumourigenic differences of these SNPs 
have been ascribed largely to those within the E6 oncogene [Zehbe et al., 1998a; 1998b; 2001; 
Grodzki et al., 2006]. The Asian-American (AAE6) and European Prototype (EPE6) are common 
HPV16 genome variants which differ by six SNPs in their E6 genes, three of which are non-
synonymous, leading to the 151-residue AAE6 protein differing by three amino-acids: Q14H, 
H78Y, and L83V [Cornet et al., 2012] (with residue 14 and 83 being under Darwinian constraint 
[Chen et al., 2005]). 
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 Epidemiological studies showed that the AAE6 genome variant is a higher risk factor for 
dysplasia as well as an earlier onset of invasive tumours than EPE6 [Xi et al., 1997; 2007; Villa et 
al., 2000; Berumen et al., 2001; Zuna et al., 2009; Schiffman et al., 2007; Freitas et al., 2014]. As 
well, AAE6 has a greater transforming, migratory, and invasive potential than EPE6 when 
retrovirally transduced into primary human keratinocytes during recent long-term in vitro 
immortalization studies [Zehbe et al., 2009; Richard et al., 2010; Niccoli et al., 2012; Togtema et 
al., 2015]. These results suggested that coding changes in E6 have strong mechanistic and 
functional consequences for infection and thus contribute to marked differences in cancer risk of 
HPV16 variants. 
 To decipher the fundamental biology of HPVs and their tumourigenic features in a model 
system, the organotypic 3D infection model (raft culture) has the advantage of allowing 
reproducible and simultaneous epithelial differentiation and hence the occurrence of an active viral 
life cycle [Jackson et al., 2014; Figure 2.1]. Thus, using engineered human epithelium resembling 
in vivo conditions based on near-diploid immortalized keratinocytes (NIKS) [Allen-Hoffmann et 
al., 2000] we recently elucidated the phenotypic characteristics of both E6 gene variants in the 
context of the full HPV16 genome [Jackson et al., 2014], building upon previous work on the 
effects of transduction with the E6 or E6/E7 genes only [Zehbe et al., 2009; Richard et al., 2010; 
Schütze et al., 2014]. Using the organotypic model we observed that the AAE6 genome drives 
tumourigenesis by increasing epithelial proliferation, disrupting routine differentiation and 
apoptosis, evading the innate immune system and promoting immortalization [Jackson et al., 
2014]. Interestingly, we also observed that the differences in host epithelia histologically classified 
as mild keratinizing (EPE6) or moderate (AAE6) dysplasia were reflective of increased oncogene 
(E6 and E7) expression in AAE6 cultures and loss of productive life cycle (decreased E2, E1^E4, 
and L2). Together these observations lead us to suspect integration of the AAE6 viral DNA into 
the host genome [Jackson et al., 2014], a common phenomenon during HPV-induced 
tumourigenesis (reviewed in [Poreba et al., 2011]). 
 Here, to further advance our mechanistic understanding of the impact of these common but 
epidemiologically and clinically important E6 SNPs, we conducted an “-omics” analysis on the 
NIKS-based organotypic epithelia containing the HPV16 variants AAE6 and EPE6 [Figure 2.1]. 
Modern deep sequencing techniques have been used to study HPV [Mine et al., 2013; Khoury et 
al., 2013; Bryant et al., 2014; Chandrani et al., 2015; Cullen et al., 2015], but only recently in the 
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context of intratypic variants [Lavezzo et al., 2016], and not using an organotypic epithelial model 
with full viral variant genomes. Instead, our complete approach allowed a comparison of these 
variants with regards to their integration capacity and subsequent transcriptional consequences in 
close to in vivo conditions, resulting in viral integration and a molecular signature of host 




Figure 2.1 – The HPV16 genome and our experimental epithelial model. Contained within the 
viral protein capsid (top left, not to scale relative to skin) is the 7.9 kb HPV16 genome, comprised 
of eight viral genes. Over a 14-day differentiation process we grew three-dimensional organotypic 
epithelia, or raft cultures, using near-diploid immortalized keratinocytes (NIKS) and primary 
human fibroblasts embedded in collagen-based dermal matrix. To permit the viral life cycle in this 
culture system we transfected the keratinocytes, prior to rafting, with complete viral genomes 
containing either the European Prototype or Asian-American variant of HPV16 E6 (EPE6 or 
AAE6, respectively). NIKS represented normal epithelia, NIKS with HPV16 EPE6 was a mild 
dysplasia (indicated by thickening and some suprabasal proliferation), whereas NIKS with HPV16 
AAE6 was a moderate dysplasia (indicated by a greater number of suprabasal proliferating cells 
and abnormal cellular phenotypes, including micronuclei). Additionally, HPV16 viral integration 
was detected in AAE6 epithelia.  
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2.3 – Results and Discussion 
2.3.1 – Viral integration in the HPV16 AAE6 but not EPE6 epithelium 
To permit the viral life cycle in a raft culture system, we transfected the keratinocytes, prior 
to rafting, with complete viral genomes containing either the HPV16 EPE6 or AAE6 variant. A 
similar technique was used in a recent study to successfully study varicella zoster virus [Jones et 
al., 2014], providing a keratinocyte model and a “global” perspective of all changes in host 
transcription in response to a pathogen. As illustrated in Figure 2.1, over a 14-day differentiation 
process, we observed that the NIKS were normal epithelia whereas NIKS with HPV16 EPE6 
exhibited a mild dysplasia and NIKS with HPV16 AAE6 exhibited a moderate dysplasia. 
To examine the HPV status of these cells we used the highly sensitive and high-throughput 
DNA capture and sequencing technique named Capt-HPV [Holmes et al., 2016]. We prepared 
genomic DNA from epithelia of both EPE6 and AAE6. Then, after double capture on the HPV 
probes, we performed 2 x 151 nt paired-end sequencing (see 2.5 – Methods). As expected, we 
readily identified numerous HPV reads in both epithelial cultures. The sequencing reads of the E6 
coding region confirmed the positive infection of the epithelia by the AAE6 and EPE6 variants. 
However, as we hypothesized [Jackson et al., 2014], the physical genomic status of HPV was 
clearly different. In the EPE6 epithelia, the reads covered the entire HPV genome indicative of its 
episomal state [Figure 2.2a] whereas only a fraction of the virus genome was detectable in the 
AAE6 epithelia, indicative of its integration into the host genome. Furthermore, in the case of 
EPE6, no human-viral junction reads were detected while the integrated AAE6 viral genome was 
truncated and several human-viral junction reads were identified in AAE6 epithelia. The integrated 
viral sequence was from nt 2453 (within HPV16 E1 gene) and nt 5780 (within HPV16 L1 gene) 
and thus includes the E6 and E7 oncogenes. Precisely, the insertion of the HPV16 AAE6 variant 
occurred between the nt position 149,347,294 and 149,347,305 of chromosome 5. Mechanistically, 
this is a simple “end-out” integration event with a typical two junction, co-linear (2J-COL) 
signature [Holmes et al., 2016], associated with a very short 11 bp deletion of the host genome, 
and two overlapping nucleotides between viral and human sequence at each junction [Figure 
2.2a]. Functionally, the insertion occurred within the 5q32 sub-band region, and more precisely, 
within the first intron of the SLC26A2 gene, approximately 13 kb upstream of its third exon. 
Based on the Dr.VIS (Viral Integration Site) v2.0 database of HPV16 integration sites 
[Yang et al., 2015], this exact region (5q32) of integration is not frequent, but potentially recurrent 
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as it was found in 2 out of 878 previously documented sites. The nearest fragile site was 13 Mb 
upstream of this integration site: FRA5C, 5q31.1. Since repeated regions might be prone to genome 
rearrangements and therefore prone to HPV integration, we scanned the adjacent regions using the 
UCSC hg19 genome browser RepeatMasker track for human repeat elements and found a nearby 
158 bp long interspersed nuclear element (LINE): L1MB5 located from Chr5 nt position 
149,347,143 to 149,347,300. Indeed, L1MB5-derived sequences have been documented as 
breakpoints, such as in the human genes HPRT [Williams et al., 2002], CYP2C [Zhou, 2016], and 
in proximity of genes containing the ubiquitin ligase Mib-herc2 domain, which mediates Notch 
signalling [del Rosario et al., 2014]. Strikingly, this domain contains the Hect region, homologous 
to the E6-associated protein carboxyl terminus, raising the question of whether or not the 
underlying homology could play a role in this target site selection. Another, non-exclusive 
hypothesis is that the frequent hypo-methylation of LINE elements plays a role to facilitate access 
to the chromosomal DNA and associated genomic instability [Richards et al., 2009; Baba et al., 
2014]. Altogether, our three-dimensional organotypic cultures demonstrated that the HPV16 
AAE6 variant had integrated into the host genome while the EPE6 variant remained episomal, 
suggesting an increased propensity towards integration due to AAE6. A previous study of HPV16 
integration propensity with respect to the variants did not demonstrate a statistically significant 
difference (P = 0.28, two-tailed Fisher’s exact test) between EPE6 (3 episomal and 20 integrated 
cases) and the E-T350G variant (6 episomal and 16 integrated cases, responsible for one of the 
residue changes also found in AAE6: L83V) [Xu et al., 2013]. Only one tumour sample in their 
set contained the AA variant, therefore precluding a formal analysis of its propensity to integrate, 









Figure 2.2 – Characterization of viral integration and viral-human fusion transcripts in 
AAE6 epithelia. [a] Integration site schematic showing viral and human junctions, including 
nucleotide positions, the early promotor, as well as viral-human fusion transcript between HPV16 
early region and SLC26A2 exon 3. A coverage plot above the integrated HPV16 genome 
demonstrates coverage across the junction sites within SLC26A2 (5482 reads across a 4978 nt 
assembly containing the AAE6 integrated form flanked by 200 nt of SLC26A2), while a circular 
coverage plot on the right shows the full episomal assembly of the EPE6 episomal form. [b] 
Immunofluorescence overlays of EPE6 and AAE6 raft cultures (400x magnification). Nuclei are 





2.3.2 – The HPV16 AAE6 epithelium has a unique transcriptional profile 
 Another essential feature that may differentiate the behaviour of the HPV16 EPE6 and 
AAE6 variants is expression of the viral genome, viral-human fusion transcripts when integrated, 
as well as downstream host effects due to expression of the E6/E7 oncogenes. To assess these, we 
performed a genome-wide RNA-Seq analysis of the EPE6 and AAE6 epithelia using Illumina 
sequencing of total RNAs (see Methods), mapping first against our reference HPV16 W12E 
genome [GenBank AF125673]. Viral transcriptomes were visualized with the Integrative 
Genomics Viewer (IGV) [Robinson et al., 2011], while viral gene counts and variant calls were 
performed using SAMtools [Li et al., 2009]. The average sequencing depth of 40.4 million total 
reads per sample (~20 to 25 million fragments producing paired-end reads) was appropriate to 
detect the small proportion of total reads of both HPV variant genomes (~0.0001 to 0.01%, 
Additional file 1: Table 2.S1), while none were detected in the HPV-negative control epithelium. 
The variant-specific non-synonymous SNPs (relative to the reference HPV16 W12E genome) 
present in EPE6 (G350T) and AAE6 (G145T+C335T) were confirmed with depth of reads of 6x 
for EPE6 and with 14x to ~300x depth of reads for AAE6. Among the EPE6 epithelial samples, 
we detected few E6, E6*I (spliced transcript), E7, E1, E2, E1^E4, and E5 transcripts, with even 
fewer L2 and L1 reads, as confirmed by L2 RT-qPCR and L2 protein immunohistochemistry 
results from the same independent set of rafts reported previously [Jackson et al., 2014]. Among 
the three individual epithelial raft cultures for EPE6 samples the viral transcriptional landscape 
appeared similar but the read coverage was higher in raft #2 due to an overall higher abundance of 
viral transcripts in this sample [Figure 2.3a]. In contrast, the transcriptional landscape for the three 
AAE6 samples was more homogenous [Figure 2.3a], further emphasized in a clustered heatmap 
[Figure 2.3b]. Abundant full-length E6, E6*I, E7, and only truncated E1 and L1 transcripts were 
detected. Full-length E1, E2, E1^E4, and L2 reads were absent in AAE6 epithelia, consistent with 
the Capt-HPV data reported above and our previous RT-qPCR results and DNA copy number 
analyses on these molecules [Jackson et al., 2014]. 
 To quantitatively account for sample variance, we also performed differential expression 
analysis of the viral gene counts using DESeq [Anders and Huber, 2010]. DESeq software tests 
for differential expression in library size-corrected count data using a negative binomial 
distribution model. In agreement with our previous RT-qPCR results [Jackson et al., 2014], we 
found significantly more E6 (24.05 fold higher, P < 10−10) and E7 (17.30 fold higher, P < 10−10) 
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counts in triplicate AAE6 rafts in comparison to triplicate EPE6 rafts [Figure 2.3c]. Taken 
together, analyses of viral transcriptome data revealed that the AAE6 viral transcriptome 
significantly differs from that of EPE6 in a manner that is indicative of integration, with increased 
E6 and E7 levels [Dürst et al., 1991; Jeon et al., 1995; Daniel et al., 1997]. Evidently, AAE6 
transcriptome profiles are lacking E2 and have increased E6/E7 oncogene expression, perhaps due 
to loss of transcriptional repression by E2. We therefore reasoned that the increased levels of E6/E7 
expression between the variants were ultimately due to their viral integration status, as we 
hypothesized in our phenotypic study, and confirmed by Capt-HPV, leading to a significant effect 







Figure 2.3 – The HPV16 transcriptome in EPE6 and AAE6 organotypic rafts. [a] Linear viral 
gene map. Viral RefSeq ([GenBank: AF125673], HPV16 W12E genome) alignment from each 
individual raft culture was visualized using IGV [Robinson et al., 2011]. The y-axis (coverage) is 
log2 scaled. Total number of viral reads are given on the right-hand side of each track. [b] Heatmap 
& clustering analysis of viral transcriptome on DESeq normalized counts: viral genes vs sample 
replicates. Two distinct sample clusters matched EPE6 and AAE6 replicates respectively, 
clustering independently of each other. Within the high-variability EPE6 cluster, replicate 1 and 3 
were clustered together. Within the low-variability AAE6 cluster, replicate 1 and 2 were clustered 
together. As well, AAE6 epithelia converged on consistently high viral transcription (specifically 
E6/E7). From the viral gene perspective, two distinct clusters were identified: E6, E7, E1, and L1 
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in one, and E2, E4, E5, and L2 in another. Within the first primary cluster, E6 and E7 cluster close 
together, as expected given they are expressed together as a multi-cistronic transcript. E1 and L1 
also cluster together, constituting the truncated transcripts on the periphery of the non-transcribed 
region within AAE6 samples. In the second primary cluster, E5 and L2 cluster together, 
independent of E2 and E4 which is transcribed only in EPE6 samples. E2 and E4 expression 
unsurprisingly clusters together given that E4 is contained within the E2 ORF. [c] Scatterplot of 
average viral gene expression for EPE6 samples (x-axis) and AAE6 samples (y-axis). The axes 
(DESeq normalized gene counts) are log10 scaled. Significant differential gene expression is 





2.3.3 – Nature of viral-human fusion transcripts detected in HPV16 AAE6 epithelium 
 The integration of HPV16 genomes into host chromosomes is a frequent phenomenon 
associated with carcinogenesis, and not only modifies the expression of HPV-encoded E6 and E7 
oncogenes [Figure 2.3a] but can also trigger the expression of fusion viral-human mRNAs [Poreba 
et al., 2011; Lace et al., 2011]. Since the virus can integrate into a variety of positions in the human 
genome, these fusion transcripts are specific to each integration site. In recent years, following the 
introduction of high-throughput sequencing techniques, multiple software for detecting pathogen 
sequences in host sequence data have become available [Hawkins et al., 2011; Westermann et al., 
2012; Bonfert et al., 2013; Chen et al., 2013; Li et al., 2013; Wang et al., 2013; Katz and Pipas, 
2014; Chandrani et al., 2015]. Here, to identify the viral-human fusion transcripts expressed in our 
epithelia, we used the ViralFusionSeq (VFS) software [Li et al., 2013; Lau et al., 2014]. VFS was 
chosen over alternatives due to its optimization for RNA-Seq data from the Illumina platform, the 
ability to define our own reference virus genome, as well as the full suite of fusion transcript 
discovery techniques it uses. Using this technique, only the AAE6 rafts yielded viral-human fusion 
transcripts [Table 2.1], providing further evidence of viral integration as well as its transcriptional 
impact. 
 In accordance with the structure of the HPV integration, the transcript breakpoints mapped 
to either the E1 or L1 HPV16 ORF. Alternative splicing was detected with the viral nucleotide 
position at the fusion site of one class of the viral-human fusion transcripts [Figure 2.3a]: nt 880 
(splice donor, SD) in the E1 gene [Johansson and Schwartz, 2013]. This is the same SD site for 
the E1^E4 splice transcript typically expressed in the late stage of the viral life cycle [Doorbar, 
2005], and previously shown to be expressed in our EPE6 epithelia [Jackson et al., 2014]. HPV16 
viral-human fusion transcripts are often detected with a breakpoint at this natural splice donor site 
[Wentzensen et al., 2002; Kraus et al., 2008; Lace et al., 2011], and the coverage plot for AAE6 
shows decreased coverage for transcripts downstream of this E1 SD site, supporting the hypothesis 
of alternative splicing. With respect to the L1 breakpoints, the typical L1 splice acceptor (SA) site 
is at nt 5639 [Johansson and Schwartz, 2013], but notably in our study, the viral-human fusion 
transcripts here had a putative downstream SA site at nt 5778. Interestingly, the coverage plot of 
the viral transcriptome shows nt 5778 as the site where L1 coverage begins to be detected in AAE6 
rafts [Figure 2.3a], so we reasoned that this discrepancy in SA site could be due to either a cryptic 
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SA site in the HPV16 W12E genome (although not found previously in the literature) or simply 
due to integration truncating the upstream region of L1. 
 Next, we mapped the human portion of the fusion transcripts using VFS’s clipped-seq (CS) 
and read-pair (RP) methods. Confirmed by both these methods, two fusions mapped to the human 
chromosome location 5q32, occurring within the solute carrier family 26 (anion exchanger), 
member 2 (SLC26A2) and phosphodiesterase 6A, cGMP-specific, rod, alpha (PDE6A) human 
ORFs [Table 2.1]. Strikingly, along with detection of fusion transcripts with these genes, we 
detected a significant increase in the expression of human genes from this region in AAE6 epithelia 
compared to normal epithelia, namely SLC26A2 (114.19 fold increase, P = 2.14 x 10−173) and 
colony-stimulating factor 1 receptor (CSF1R, 407.82 fold increase, P = 4.70 x 10−112, which was 
only detected as RP fusion reads by VFS, and not confirmed by CS). This observation is in 
agreement with others who have found that, in numerous cervical carcinomas across multiple high-
risk HPV types, HPV integration leads to an increase in the expression of genes adjacent to 
integration loci [Ojesina et al., 2014]. To explain the molecular basis of this cis-effect, it has been 
proposed to be the result of viral promotor-driven expression or somatic genome amplification at 
the integration site [Peter et al., 2010; Akagi et al., 2014]. In the present case, this last hypothesis 
is unlikely because the AAE6 integration produced a clean 11 bp deletion of the target region that 
led to two co-linear viral-human junctions (2J-COL), which is not associated with gene 
amplification [Holmes et al., 2016]. 
 Functional human fusion proteins can be formed due to chromosomal translocations in 
cancer cells [Rabbitts, 1994]. The elucidation of novel protein-coding viral-human fusion 
transcripts is particularly intriguing due to their potentially functional roles within host cells. Using 
immunofluorescence for the expressed portion of the SLC26A2 protein in formalin-fixed and 
paraffin embedded (FFPE) rafts, we determined that SLC26A2 protein expression was aberrantly 
high in AAE6 compared to EPE6, supposedly as a result of its viral-human fusion and increased 
transcription [Figure 2.2b]. This translated fusion protein contains exon 3 of the transmembrane 
protein SLC26A2, previously known as diastrophic dysplasia sulfate transporter (DTDST) 
[Hästbacka et al., 1999], which encodes the carboxy-terminal cytoplasmic sulfate transporter and 
anti-sigma factor (STAS) domain [Sharma et al., 2011]. We cannot find any evidence in the 
literature of this unique viral-human fusion protein in other HPV-integrated samples. Overall, 
these chimeric molecules are unique for each sample and to the specific integration site, with 
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presently unknown effect on host cell functions, an aspect to be further researched due to its 
importance for understanding mechanisms of tumourigenesis as well as in the emerging field of 
personalized medicine. 
 
Table 2.1 – Integration loci detected by ViralFusionSeq. Viral-human fusion transcripts were 
discovered using ViralFusionSeq’s [Li et al., 2013]: clipped-sequence (CS) and read-pair (RP) 
modules. Detected by at least 1 RP and CS event (†). As detected by CS method (‡). VFS uses 
two methods to detect viral-human fusion transcripts. The Clipped-Seq (CS) method detects viral 
fusion transcript breakpoints with a read that maps to both viral and human sequences, while the 
Read-Pair (RP) analysis detects transcripts with read ends mapped separately to the viral and 
human genome [Li et al., 2013]. We required candidate viral fusion transcripts to be supported by 
at least 1 CS and 1 RP event in order to improve its stringency [Lau et al., 2014]. Although RP 
events were more abundant in our samples, CS analysis provided single-base resolution of viral-
human fusion transcript breakpoints. In particular, we identified an average of 1.33 +/− 1.53 CS 
transcripts in EPE6 and 7.66 +/− 6.66 in AAE6. We detected no RP transcripts in EPE6, while 
118.66 +/− 7.23 were found in AAE6 rafts. While one RP transcript was detected in a NIKS control 
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2.3.4 – The HPV16 AAE6 epithelium reveals a signature of chromosomal instability conducive to 
host genome integration 
 Integration of HPV DNA into the host genome is considered to be a key factor for cervical 
cancer development [Wentzensen et al., 2002; Pett and Coleman, 2007; Bodelon et al., 2016], but 
the cellular events that initiate the integration process (and selection of insertion sites) remain to 
be better understood. A reasonable hypothesis is that the integration is triggered by a rare and 
stochastic target site event, such as a replicative fork stalling or an accidental chromosome double-
strand break, leading to an ultimate use of the viral DNA for repair via recombination, template 
switching (FoSTeS) and/or microhomology-mediated break-induced replication (MMBIR) 
([Akagi et al., 2014; Hu et al., 2015; Holmes et al., 2016], and references within each). Indeed, 
infections with pathogens can cause chromosomal instability by inactivating the host DNA damage 
response [Weitzman and Weitzman, 2014]. For HPV, this has been linked to the expression of 
both HPV16 E6 and E7 oncoproteins, affecting the infected cell’s genome integrity [White et al., 
1994; Kessis et al., 1996; Duensing et al., 2000; Duensing and Münger, 2002]. A model of early 
carcinogenesis due to HPV16 E6 and E7 suggests that this chromosomal instability is caused by 
uncontrolled proliferation, leading to an insufficient nucleotide pool that cannot support normal 
replication [Bester et al., 2011]. Alternatively, E6 alone, through the inactivation of p53, can 
promote chromosomal instability, at least during early onset of carcinogenesis [Havre et al., 1995]. 
Presently, HPV16 AAE6 demonstrated enhanced integration propensity over EPE6 and exhibited 
increased E6 and E7 oncogene expression, which is in accordance with elevated E6 and E7 levels 
reported in other studies [Dürst et al., 1991; Jeon et al., 1995; Daniel et al., 1997]. This enhanced 
integration ability is based on AAE6’s greater proliferation ability, leading to chromosomal 
instability. The underlying mechanism of its increased cell growth is the result of a deregulated 
sugar metabolism (Warburg effect), as we reported previously [Richard et al., 2010] and currently 
under study [Cuninghame et al., 2017]. 
 To assess the host chromosomal instability in our HPV16 variant epithelia, we examined 
our RNA-Seq data to detect the CIN70 gene expression signature [Carter et al., 2006], which has 
been applied as a prognostic marker in cervical cancer [How et al., 2015] and more generally as a 
significant indicator to predict clinical outcome across multiple cancer types [Carter et al., 2006]. 
This signature is derived from 18 gene expression datasets (with genes ranked based on their 
correlation to functional aneuploidy). The CIN70 score relative to HPV-negative NIKS was 
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significantly higher in AAE6 compared to EPE6 epithelia (2.32 fold higher, P = 0.02 by Welch’s 
T-test), indicating a signature of host chromosomal instability in AAE6 epithelia [Figure 2.4a]. 
Furthermore, as a morphological sign of chromosomal instability, we detected micronuclei (MN) 
in AAE6 but not EPE6 or NIKS FFPE H&E-stained epithelia [Figure 2.4b]. MN were reported to 
be present in higher grade cervical intraepithelial neoplastic lesions and invasive cervical cancer 
[Samanta et al., 2011] and mechanistically have been associated with hallmarks of genomic 






Figure 2.4 – Chromosomal instability signature and micronuclei in AAE6 epithelia. [a] The 
CIN70 score relative to HPV-negative NIKS was significantly higher in AAE6 compared to EPE6 
epithelia (2.32 fold higher, P = 0.02 by Welch’s T-test). Mean values are shown with error bars 
representing standard deviation (n = 3). Statistical significance (P < 0.05) denoted by “*”. [b] 
Haematoxylin and eosin micrographs of FFPE AAE6 epithelia, 400x cropped, micronuclei 
indicated by arrow. Close-up shows micronucleus and normal-sized nucleus within same cell.  
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2.3.5 – HPV16 AAE6 epithelium exhibits a proliferating phenotype as a consequence of viral 
integration into the host genome 
 More broadly, our RNA-Seq data led us to examine global changes in host gene expression. 
Our previous study demonstrated enhanced tumourigenesis by the full HPV16 genome with AAE6 
[Jackson et al., 2014], while another study presented altered gene expression by the AA variant 
[Sichero et al., 2012]. Work by other groups have studied the downstream pathways in the AA 
variant [Hochmann et al., 2016; Zacapala-Gómez et al., 2016], and have utilized high-throughput 
techniques to investigate genetic variation within HPV16 [Cullen et al., 2015; Muller et al., 2015; 
Lavezzo et al., 2016], but this is the first study investigating the downstream pathways affected by 
the HPV16 variants in an organotypic epithelial model using next-generation sequencing. We 
hypothesized two scenarios that can be associated with these findings and analyzed in our present 
study: i) the global gene expression profile within AAE6-infected epithelium would differ 
significantly from that of EPE6 and ii) significant gene expression differences in the host due not 
only to the actions of the viral oncogenes E6 and E7, but also as a result of integration [Lace et al., 
2011]. A global “-omics” technique, RNA-Seq, was required to sufficiently address our hypotheses 
around the functional relevance of the AA variant in epithelia. We assessed host differential gene 
expression using DESeq [Anders and Huber, 2010] to determine how it reflected the unique viral 
gene expression profiles induced in human epithelium undergoing differentiation. Strikingly, 
NIKS, which contain no virus genome, had zero significant differentially expressed genes 
compared to EPE6, at a false-discovery rate (FDR) of 10% [Additional file 2: Figure 2.S1]. NIKS 
to AAE6 had 3006 significant differentially expressed genes [Additional file 2: Figure 2.S2, 
Additional file 3 for list of differentially expressed genes between NIKS and AAE6]. Of these 
genes, 1312 were down-regulated while 1694 were up-regulated in AAE6 compared to NIKS. The 
lack of any differentially expressed genes between NIKS and EPE6 organotypic epithelial cultures 
was surprising, but consistent with the similarity between the NIKS and EPE6 cultures monitored 
with respect to basal and suprabasal keratinocyte proliferation assessed by BrdU-incorporation, 
p53 and p16INK4A by immunohistochemistry and IFN-κ by RT-qPCR [Jackson et al., 2014]. 
Phenotypically, these results suggest that the episomal expression of the EPE6 variant in our model 
does not have a significant tumourigenic effect. Since our 3D culture model specifically captures 
early tumourigenesis, with only a 2-week growth period and low initial viral copy number, very 
small gene expression differences in a homogenized epidermal sample are not expected to be easily 
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detected with global transcriptomic techniques. On the other hand, AAE6 significantly perturbed 
a high number of human genes, demonstrating its ability to cause a wide-range of host molecular 
changes consistent with tumourigenesis. Compared to EPE6, AAE6 had 1666 significant 
differentially expressed genes [Additional file 2: Figure 2.S3, Additional file 3 for list of 
differentially expressed genes between EPE6 and AAE6]. Of these genes, 666 were down-
regulated while 1000 were up-regulated in AAE6 compared to EPE6. Additional discussion of the 
top-ten most significant down- and up-regulated genes for each pair-wise comparison is provided 
in Additional file 4. To further investigate the differential gene expression data we applied two 
additional bioinformatics analyses: gene ontology (GO) biological process term enrichment 
[Additional file 5 for GO output, Figures 2.5 and 2.6], as well as co-expression analysis and 
visualization using networks [Figure 2.7]. Finally, we also compared the pair-wise lists of 
differentially expressed genes to determine the number of common and unique genes among each 
set [Figure 2.8]: 1541 genes unique to the NIKS comparison, 201 unique to the EPE6 comparison, 
and 1465 common between them. Overall, these bioinformatics analyses highlight the global 
effects of AAE6 on host epithelia due to its integration event, increased E6/E7 expression, and 
perhaps in part functional differences due to the AAE6 oncoprotein itself: increased proliferation 







Figure 2.5 – Gene Ontology (GO) terms enriched in highly significant differentially 
expressed genes in AAE6 vs. NIKS. The Term Enrichment Service available on the AmiGO 2 
website [Carbon et al., 2009] was used to determine enriched GO (biological process) terms among 
[a] down-regulated and [b] up-regulated genes. Only the top ten GO terms are shown for each. 








Figure 2.6 – Gene Ontology (GO) terms enriched in highly significant differentially 
expressed genes in AAE6 vs. EPE6. The Term Enrichment Service available on the AmiGO 2 
website [Carbon et al., 2009] was used to determine enriched GO (biological process) terms among 
[a] down-regulated and [b] up-regulated genes. Only the top ten GO terms are shown for each. 






Figure 2.7 – Co-expression networks of highly significant [a] down-regulated and [b] up-
regulated genes in AAE6 vs. EPE6. [a] Four discrete clusters of down-regulated and co-
expressed genes were observed. Only co-expressed genes with a Pearson correlation coefficient 
greater than 0.95 are shown. Clusters are labelled by number and functionally annotated with their 
30 
 
significantly enriched biological process. Nodes = gene, denoted by gene symbol; node 
colour = white to red with down-regulation (fold change) in AAE6 from EPE6; edge 
thickness = increases with Pearson correlation coefficient. [b] Five discrete clusters of up-
regulated and co-expressed genes were observed. Only clusters co-expressed genes with a Pearson 
correlation coefficient greater than 0.996 and are shown, to narrow down the number of genes 
displayed. Clusters are labelled by number and functionally annotated with their significantly 
enriched biological process. Nodes = gene, denoted by gene symbol; node colour = white to green 
with up-regulation (fold change) in AAE6 over EPE6; edge thickness = increases with Pearson 
correlation coefficient. See Additional file 4 for discussion. 
 
 
Figure 2.8 – Venn diagram of differentially expressed genes common and unique to each 
pairwise comparison. Of the 3006 differentially expressed (DE) genes in NIKS vs AAE6 and the 
1666 differentially expressed (DE) genes in EPE6 vs AAE6 there were 1541 genes unique to the 
NIKS comparison, 1465 common between them, and 201 unique to the EPE6 comparison. No 
genes were up-regulated in one set of a pair-wise comparison (either NIKS vs EPE6 or EPE6 vs 
AAE6) while down-regulated in the other. 
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2.4 – Conclusions 
 We have systematically characterized the viral integration process of a common high-risk 
HPV16 variant and its consequences for the affected host cell. This and earlier work lend 
themselves to propose a model of increased tumourigenicity in human keratinocyte epithelia where 
AAE6’s enhanced ability to proliferate leads to chromosomal instability. In such an environment, 
the host genome may be susceptible to viral integration subsequently increasing E6/E7 oncogene 
expression and ultimately driving additional tumourigenic changes. Previously, we performed 
phenotypic studies of the EPE6 and AAE6 variants in a 3D raft model of early carcinogenesis 
[Jackson et al., 2014] and determined the functional differences of these variants in longitudinal 
monolayer cell cultures [Zehbe et al., 2009; Richard et al., 2010; Niccoli et al., 2012; Togtema et 
al., 2015]. While necessary for studying the viral life cycle, limitations of the current organotypic 
model are the lack of immune components, vasculature, and the complexity of tissue heterogeneity 
that arises. Our current study builds on the foundation of these investigations. We have applied a 
wide range of molecular analyses, creating a framework which can benefit future virus-host 
interaction studies with various organotypic cell culture models. A variant-specific integration is 
worth reporting and should be further investigated, with additional samples from independent 
donors, as it represents a new paradigm in HPV variant biology. Here we report a viable integration 
mechanism in a robust viral life cycle model for AAE6. The findings of the current and other 
studies reported by us [Zehbe et al., 2009; Richard et al., 2010; Niccoli et al., 2012; Jackson et al., 
2014; Togtema et al., 2015], and others [Sichero et al., 2012; Hochmann et al., 2016; Zacapala-
Gómez et al., 2016], are consistent with cancer epidemiology studies demonstrating that the 
HPV16 AA variant is a higher risk factor for high-grade intraepithelial neoplasia and progression 
to invasive cervical cancer [Berumen et al., 2001; Xi et al., 2007; Zuna et al., 2009; Sichero et al., 
2012]. In the future, HPV variant genotyping could be used as a clinical prognostic factor for 
patient-centered health services, while the role of individual host genomics on integration, 






2.5 – Methods 
2.5.1 – Cell lines 
 As described by us previously [Jackson et al., 2014], we used the Normal/Near-Diploid 
Immortalized Keratinocytes (NIKS) cell line [Allen-Hoffmann et al., 2000] to establish 3D 
organotypic epithelia cultures. These spontaneously immortalized cells were originally derived 
from neonatal human foreskin and are non-tumourigenic, though contain an additional long arm 
piece of chromosome 8 (8q). In monolayer they are grown on mitomycin-C-treated Swiss mouse 
J2/3T3 fibroblast feeder layers [Allen-Hoffmann et al., 2000], while primary human foreskin 
fibroblasts (ATCC CRL-2097) are incorporated into the dermal equivalent of organotypic NIKS 
cultures [Jackson et al., 2014]. 
 
2.5.2 – Detection of integrated papillomavirus sequences by DNA-Seq: Capt-HPV 
 DNA-Seq was used to confirm the presence and location of the viral integration sites in the 
human genome using DNA extracted from formalin-fixed paraffin embedded (FFPE) samples 
which had been prepared previously [Jackson et al., 2014]. DNA was extracted using the DNeasy 
Blood and Tissue Kit (QIAGEN, Cat# 69504) with the recommended pre-treatment for FFPE 
samples and the optional RNase treatment. To overcome the limitations of traditional techniques, 
such as DIPS-PCR (Detection of Integrated Papillomavirus Sequences by ligation mediated PCR), 
we used an unbiased and state-of-the-art next-generation DNA sequencing technique for detecting 
HPV viral integration sequences in our samples [Holmes et al., 2016]. Library preparation, 
sequence capture, and high-throughput sequencing was carried out at the Institut Curie on an 
Illumina MiSeq platform with a V2 Nano chip (~1 x 106 total reads) with 2 x 151 base pair read 
length. Analysis of sequencing data was performed using the Galaxy platform [Giardine et al., 
2005; Blankenberg et al., 2010b; Goecks et al., 2010], with the primary goal of detecting the viral-
human junction site locations. Packages used were FASTQ Groomer [Blankenberg et al., 2010a], 
Bowtie2 [Langmead and Salzberg, 2012], Picard MarkDuplicates [Picard Tools], SAMtools 
BAM-to-SAM and Filter SAM [Li et al., 2009]. 
 
2.5.3 – RNA-Seq library preparation and sequencing 
 Isolation of high-quality total RNA from the epithelium of organotypic keratinocyte 
cultures containing full-length HPV16 E6 variant genomes, European Prototype (EPE6) and 
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Asian-American (AAE6), was described previously [Jackson et al., 2014]. Our keratinocyte model 
was grown for 14 days to allow simultaneous epithelial differentiation and occurrence of an active 
viral life cycle. Total RNA for EPE6, AAE6, and HPV16 negative cultures (NIKS), three 
organotypic raft cultures (n = 3) each, were sent for library preparation and sequencing at The 
Centre for Applied Genomics, Hospital for Sick Children, Toronto, Canada. RNA-Seq libraries 
were prepared by Illumina TruSeq® RNA Sample Preparation kit followed by sequencing using 
an Illumina HiSeq® 2500 platform with Illumina v3 chemistry. One lane of multiplexed, paired-
end, 2 x 101 base pair sequencing was performed with nine samples: yielding an average of 40.4 
million total reads (~20 to 25 million fragments) per sample [Additional file 1: Table 2.S2]. 
 
2.5.4 – Viral variant read alignment, mapping, and coverage plotting 
 The human papillomavirus type 16 W12E isolate genome [GenBank: AF125673] [Jeon et 
al., 1995; Flores et al., 1999] was used as a viral reference sequence since it was the parental 
sequence modified by site-directed mutagenesis to generate the EPE6 and AAE6 viral genomes 
used in this study [Jackson et al., 2014]. Only the three non-synonymous nucleotide changes 
differentiated EPE6 and AAE6 genomes: EPE6 was made by mutating the parental W12E genome 
at G350T while AAE6 was mutated at G145T and C335T. Prior to alignment and mapping, 
Bowtie2 [Langmead and Salzberg, 2012] was used to build a reference index for HPV16 using the 
AF125673 W12E isolate RefSeq. TopHat2 [Trapnell et al., 2012] was used for alignment to our 
viral RefSeq. Variant-specific non-synonymous SNPs were confirmed by variant calling with 
SAMtools [Li et al., 2009]. The Broad Institute’s Integrative Genomics Viewer (IGV) [Robinson 
et al., 2011] was used to visualize alignment coverage for each sample. Gene-level counts of the 
HPV16 W12E ORF’s were generated using SAMtools [Li et al., 2009], and normalized with 
library-size correction factors using the Bioconductor project DESeq [Anders and Huber, 2010] in 
the statistical environment R [R Core Team, 2018]. DESeq was also used for differential viral gene 
expression analysis. DESeq uses a default false discovery rate (FDR) of 10% for its binomial 
statistical inference tests to determine differentially expressed genes. Clustered heatmaps of 





2.5.5 – Identification of viral-human fusion transcripts 
 ViralFusionSeq (VFS) [Li et al., 2013] was used, with default parameters, to identify any 
viral-human fusion transcripts in each of our sample RNA-Seq datasets. As with viral alignment 
by TopHat2 (described above), the W12E genome was used as a reference sequence for VFS. 
Briefly, VFS is a Perl script that searches in high-throughput sequencing data (RNA or DNA-Seq) 
for viral-human fusion transcripts, which are present as a result of viral integration events into host 
DNA. This software uses read pair (RP) and clipped sequences (CS) to accurately discover and 
identify viral-fusion sequences [Li et al., 2013]. Additionally, VFS is able to reconstruct fusion 
transcripts by a targeted de novo assembly process. These methods allow us to identify, with 
single-base resolution, viral-human fusion transcripts present within our epithelial cultures. Viral-
human fusion transcripts were compared to known HPV16 integration sites and fusion transcripts 
with assistance from the database of disease related viral integration sites (Dr. VIS v2.0, [Yang et 
al., 2015]). 
We sought to perform protein-level confirmation of highly expressed viral-human fusion 
transcripts containing exons from human targets SLC26A2 and CSF1R. SLC26A2 protein 
expression was detected in raft cultures by immunofluorescence, as described previously [Jackson 
et al., 2014]. Based on the viral-human fusion RNA-Seq data, the primary antibody (rabbit 
polyclonal, 1:500 dilution, Bethyl Laboratories Inc., Cat. No. A304-467A) was chosen to have 
specificity for translated exon 3 (epitope between amino acid residue 689 and 739). Although also 
highly up-regulated, no suitable commercial antibody was found for CSF1R exons 20 to 22. 
 
2.5.6 – Human read alignment, mapping, and count generation 
 Read alignment, mapping, and count generation for the human reference genome (hg19, 
UCSC nomenclature for GRCh37) was performed by The Centre for Applied Genomics, Hospital 
for Sick Children, Toronto, Canada. TopHat2 [Trapnell et al., 2012] was used for RefSeq while 
gene- and exon-level counts were generated using HTSeq [Anders et al., 2015]. Number of reads 
and percentage of human RefSeq reads defined as aligned, exon, and exon-exon are reported in 





2.5.7 – Differential expression analysis of human transcriptome 
 Differential analysis of pair-wise human gene-level counts between NIKS and EPE6, NIKS 
and AAE6, and EPE6 and AAE6 were performed using the Bioconductor project DESeq [Anders 
and Huber, 2010] package implemented in the statistical environment R [R Core Team, 2018]. 
Raw gene counts from HTSeq were first normalized by estimating the sample library sizes 
[Additional file 1: Table 2.S3] and applying the size-factor correction to all counts within a given 
sample. A dispersion plot was made to visualize the variance estimation step prior to differential 
expression inference [Additional file 2: Figure 2.S4]. A clustered heatmap with hierarchical 
dendrograms was used to show overall sample and biological replicate clustering: the gene 
expression profile of AAE6 samples was distinct from EPE6 and NIKS (control) samples 
[Additional file 2: Figure 2.S5]. Although EPE6 replicate 3 and NIKS replicate 1 cluster outside 
of their specific sample group, viral RNA-Seq analysis has confirmed these sample ID’s are 
correct, and that their grouping is likely a result of the minor host transcriptomic difference 
between NIKS and EPE6 cultures. DESeq uses a default false discovery rate (FDR) of 10% for its 
binomial statistical inference tests to determine differentially expressed genes. However, for 
downstream analyses of down- and up-regulated genes we used a more stringent adjusted P-value 
cut-off of 10−5. 
 
2.5.8 – CIN70 scoring and micronuclei detection 
 Host chromosomal instability was assessed, using normalized human gene count data from 
our RNA-Seq experiments, by calculating a CIN70 gene expression signature score [Carter et al., 
2006] for EPE6 and AAE6 relative to NIKS epithelia. For each of the 70 genes, a normalized 
human gene count ratio was calculated for all EPE6 and AAE6 samples relative to the average of 
the NIKS samples. Relative ratio values were then averaged for all 70 genes in each sample and a 
Welch’s T-test, for unequal variance, was used to determine whether there was a statistically 
significant difference in host chromosomal instability signature between EPE6 and AAE6 
epithelia. We used a significance level of P < 0.05. As a morphological assessment of 
chromosomal instability we screened haematoxylin and eosin-stained sections from formalin-fixed 
and paraffin-embedded NIKS, EPE6, and AAE6 epithelia for micronuclei (MN). These aberrant 
nuclei structures [Zhang et al., 2015] were detected using light microscopy with high-
magnification (at least 400x). 
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2.5.9 – Gene set enrichment analysis and networks 
 Enrichment of host biological processes of differentially expressed human genes was 
determined using the Gene Ontology (GO) Term Enrichment Service hosted on the AmiGO 2 
website [Carbon et al., 2009]. Only biological processes were included. Terms were considered 
significantly enriched if the Bonferroni-corrected P-value was less than 0.05. To aid in the visual 
interpretation of down- and up-regulated gene sets, co-expression networks were constructed with 
Cytoscape software [Smoot et al., 2011]. Pearson correlation coefficients were calculated for each 
gene-gene pairwise comparison in highly significant down- and up-regulated genes between AAE6 
and EPE6 [Additional file 6 for down- and up-regulated gene-gene pairwise comparisons, 
respectively]. Pearson correlation coefficient cut-offs used for networking were selected 
strategically to produce small distinct clusters of genes, since setting the threshold too low results 
in all nodes connected, and setting the threshold too high results in a lack of clusters. 
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2.7 – Additional Files 
2.7.1 – Additional file 1: Viral and human read tables 




Table 2.S1 – Viral reads summary. Overall, viral reads make up ~0.0001 to 0.01% of the total 
reads, while human reads make up 80 to 85% of the total reads (the remaining reads are unmapped, 
to either viral or human sequences). 
 
Sample Viral Reads Total Reads % 
EPE6-1 66 46.029 x 106 0.00014 
EPE6-2 2014 37.344 x 106 0.00539 
EPE6-3 117 36.182 x 106 0.00032 
AAE6-1 4505 37.518 x 106 0.01201 
AAE6-2 4029 39.224 x 106 0.01027 






Table 2.S2 – Human RefSeq alignment statistics for all samples. NIKS were HPV16 negative 
organotypic keratinocyte cultures while EPE6 and AAE6 were cultures containing the full genome 
of HPV16 with either European Prototype E6 or Asian-American E6 variants, respectively. 
“Aligned” refers to reads overlapping exons, “Exon” refers to reads completely within an exon, 

















NIKS-1 41.438 33.133 16.198 16.935 79.958 48.888 51.112 
NIKS-2 41.729 33.103 15.930 17.172 79.328 48.124 51.876 
NIKS-3 42.202 33.082 15.943 17.140 78.390 48.191 51.809 
EPE6-1 46.029 36.888 17.940 18.948 80.143 48.634 51.366 
EPE6-2 37.344 30.845 15.137 15.708 82.596 49.074 50.926 
EPE6-3 36.182 30.983 15.348 15.635 85.630 49.538 50.462 
AAE6-1 37.518 31.803 15.400 16.403 84.769 48.423 51.577 
AAE6-2 39.224 33.213 16.117 17.096 84.674 48.527 51.473 
AAE6-3 42.050 35.122 17.114 18.008 83.525 48.728 51.272 
 
 
Table 2.S3 – Human library size factor for all samples. Library size factors derived from DESeq 
[Anders and Huber, 2010]. 
 














2.7.2 – Additional file 2: DESeq plots 







Figure 2.S1 – Plot of normalized mean counts versus log2 fold change for the contrast NIKS 
versus EPE6. Red points would represent genes that have significant differential expression 
between the two conditions (false-discovery rate of 10%, adjusted P < 0.1). No genes were 












Figure 2.S2 – Plot of normalized mean counts versus log2 fold change for the contrast NIKS 
versus AAE6. Red points represent genes that have significant differential expression between the 
two conditions (false-discovery rate of 10%, adjusted P < 0.1). In total, 3006 genes were 












Figure 2.S3 – Plot of normalized mean counts versus log2 fold change for the contrast EPE6 
versus AAE6. Red points represent genes that have significant differential expression between the 
two conditions (false-discovery rate of 10%, adjusted P < 0.1). In total, 1666 genes were 












Figure 2.S4 – Empirical and fitted dispersion values plotted against the mean of the 
normalized human gene-level counts. Red line represents fitted dispersion over the empirical 






Figure 2.S5 – Heatmap of Euclidean distances between human gene-level counts of samples. 
Heatmap and clustering was performed after DESeq variance-stabilizing transformation of human 





2.7.3 – Additional file 3: DESeq output 
Significant differential expression output for NIKS and AAE6 contrast as well as EPE6 




2.7.4 – Additional file 4: Follow-up discussion of host expression analysis 
Additional discussion of differential gene expression analysis, pathway-level enrichment, 
and co-expression networks; available for download (DOCX file, 30 kb): https://static-
content.springer.com/esm/art%3A10.1186%2Fs12864-016-3203-
3/MediaObjects/12864_2016_3203_MOESM4_ESM.docx  
From the top-ten most significant down-regulated genes in AAE6 compared to NIKS 
[Table 2.S4], CYFIP2 encodes a known p53 target [Jackson II et al., 2007] and may be suppressed 
to prevent apoptosis, or perhaps even be down-regulated as a result of integration as it is located 
on chromosome 5q33.3. Kelley et al., [2005] noted CYFIP2 as significantly altered by siRNA 
against E6 or E6AP in HeLa and CaSki cells, likely due to p53 inactivation. A potential biomarker 
for cervical cancer, AJAP1, has been previously found to be silenced by methylation and 
implicated in beta-catenin signaling [Chen et al., 2014]. The transcription factor POU2F3 regulates 
keratinocyte differentiation and proliferation, encodes a candidate tumour suppressor protein, with 
silencing by promoter methylation suspected to play a role in cervical cancer [Zhang et al., 2006]. 
Of the top up-regulated genes in AAE6 compared to NIKS [Table 2.S5], both SLC26A2 and 
CSF1R are likely increased as a consequence of viral integration into chromosome 5. Interferon-
induced IFITM1 is down-regulated in our AAE6 epithelia, which is consistent with a previous 
report that assessed gene expression in HPV-infected head and neck cancers [Schlecht et al., 2007]. 
The detection of down-regulated RMI2, encoding for a protein involved in homologous 
recombination [Deans and West, 2011], could be related to increased genome instability (a 
possible mechanism for integration). EPE6 to AAE6 had 1,666 significant differentially expressed 
genes [Additional file 2: Figure 2.S3, Additional file 3 for list of differentially expressed genes 
between EPE6 and AAE6]. Of these genes, 666 were down-regulated while 1,000 were up-
regulated in AAE6 compared to EPE6. The top-ten down-regulated genes in AAE6 compared to 
EPE6 are presented in Table 2.S6 and include 6 of the same genes as found in the AAE6 to NIKS 
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comparison. The top-ten significant up-regulated genes in AAE6 compared to EPE6 are presented 
in Table 2.S7 and include 8 of the same genes as found in the AAE6 to NIKS comparison. 
To increase the stringency of differentially expressed genes we separated down-regulated 
and up-regulated genes from each pairwise comparison below the adjusted P-value threshold of 
10-5. For genes differentially expressed in AAE6 compared to NIKS, the stringent cut-off yielded 
61 down-regulated genes (61/1,312 = 4.65% highly significant down-regulated genes) and 248 up-
regulated genes (248/1,694 = 14.64% highly significant up-regulated genes). For genes 
differentially expressed in AAE6 compared to EPE6, the stringent cut-off yielded 26 down-
regulated genes (26/666 = 3.90% highly significant down-regulated genes) and 152 up-regulated 
genes (152/1,000 = 15.20% highly significant up-regulated genes). With only highly significant 
differentially expressed genes identified, we then proceeded to pathway-level analysis to 
determine which host biological processes were enriched given down-regulated and up-regulated 
sets of genes. 
Enrichment of host biological processes within the highly significant sub-sets of 
differentially expressed human genes was determined using the Gene Ontology (GO) Term 
Enrichment Service hosted on the AmiGO 2 website [Carbon et al., 2009]. Terms were considered 
significantly enriched if the Bonferroni-corrected P-value was less than 0.05. In total, 50 GO terms 
were significantly enriched among highly significant down-regulated genes in AAE6 compared to 
NIKS [Figure 2.5a for top-ten, Additional file 5 for full list]. Enrichment of these biological 
processes among highly significant down-regulated genes reflects the poor differentiation and 
tumourigenic tissue phenotype caused by AAE6 [Jackson et al., 2014], now evidenced by 
transcriptome-level data. Additionally, 176 GO terms were significantly enriched among highly-
significant up-regulated genes [Figure 2.5a for top-ten, Additional file 5 for full list], reflecting 
the proliferative phenotype caused by AAE6 [Jackson et al., 2014] and providing further evidence 
for variant-specific transcriptome-wide changes. 
When comparing AAE6 to EPE6, only 4 GO terms were significantly enriched among 
highly significant down-regulated genes [Figure 2.6a, Additional file 5 for full list]. Enrichment 
of these lipid metabolism biological processes among highly significant down-regulated genes is 
a finding that sheds new light on HPV-centered host-pathogen interactions and HPV-driven 
tumourigenesis. Notable down-regulated genes were ALDH1A1/A2. These aldehyde 
dehydrogenases catalyze the synthesis of retinoic acid which interestingly suppresses viral 
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oncogene expression [Faluhelyi et al., 2004]. A decrease of their expression could perhaps be 
permitting, at least in part, to the continued over-expression of oncogenes by AAE6. For highly 
significant up-regulated genes in AAE6 compared to EPE6, 231 GO terms were significantly 
enriched [Figure 2.6a for top-ten, Additional file 5 for full list]. Enrichment of cell cycle and 
proliferation biological processes was confirmed in AAE6 over EPE6, further demonstrating 
AAE6’s enhanced tumourigenic potential over EPE6 [Jackson et al., 2014], thought to be due in 
part to an enhanced Warburg effect [Cuninghame et al, 2017]. Pathway-level analysis revealed 
that many of the changes due to AAE6 were related to increased cell cycle and DNA synthesis, 
which are commonly promoted pathways in tumourigenesis [Hanahan and Weinberg, 2000; 2011], 
and more specifically, viral tumourigenesis [Mesri et al., 2014]. In the synthesis of DNA pathway, 
for example, nearly every gene is up-regulated, with the exception of lower CDKN1A (coding for 
p21). This potent cyclin-dependent kinase inhibitor is functionally regulated by p53, with its down-
regulation associated with invasive cervical cancer [Bahnassy et al., 2006]. 
In addition to pathway-level analysis, Cytoscape was used for visualization of co-expressed 
genes from the highly significant down- and up-regulated genes in AAE6 compared to EPE6. 
Visualizations and interpretations with networks, including co-expression networks, can play an 
important role in analyzing the large amount of data generated from high-throughput experiments 
[Merico et al., 2009] since multiple levels of information can be presented simultaneously (such 
as the degree of gene co-expression, fold change, and functional annotations). The co-expression 
network for down-regulated genes reveals four distinct clusters of genes [Figure 2.7a]. The 
strongest correlation in the first cluster was between KIAA0040 (an uncharacterized protein) and 
LIPG (lipase, endothelial), while WDR63 (WD repeat domain 63) was the most down-regulated 
due to AAE6. In the second cluster, the strongest correlation was between CYP4F22 (cytochrome 
P450, family 4, subfamily F, polypeptide 22) and KRT6B (keratin 6B). CYP4F22, a cytochrome 
P450, is likely involved in keratinocyte differentiation [Sasaki et al., 2012], so it is not surprising 
that it is strongly correlated to a cytokeratin. Mutations of this cytochrome gene lead to the skin 
disorder ichthyosis (scaly skin) [Fischer, 2009], which further supports it has a role in keratinocyte 
differentiation. The most down-regulated gene in this second cluster was AJAP1, discussed above 
as a methylated gene in cervical cancer. In the third down-regulated cluster the strongest 
correlation was between INPP5D (inositol polyphosphate-5-phosphatase) and LOC375010 
(ankyrin repeat domain 20 family, member A pseudogene). INPP5D is a negative regulator of the 
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PI3K (phosphoinositide 3-kinase) pathway [Huang et al., 2012], a common pathway involved in 
proliferation and tumourigenesis, so INPP5D’s down-regulation coincides with the tumourigenic 
potential of AAE6. The most down-regulated gene in this cluster was DAPK1 (death-associated 
protein kinase 1), which is another gene that is known to have its promoter methylated in cervical 
cancer [Banzai et al., 2014]. The fourth cluster of down-regulated genes contained only two genes: 
ANTXR2 (anthrax toxin receptor 2) and CSMD3 (CUB and sushi multiple domains). ANTXR2 
binds to extracellular matrix (ECM) proteins collagen IV and laminin, which suggests it may have 
a role in ECM adhesion in mouse studies [Reeves et al., 2013]. Interestingly, CSMD3 has been 
associated with the fragile site FRA8C at chromosome 8q24 in cervical carcinoma with HPV 
integration [Ferber et al., 2004]. 
Looking at the highly significant and co-expressed up-regulated genes, five distinct clusters 
were observed [Figure 2.7a]. The first cluster was significantly enriched for “DNA replication” 
(GO:0006260) due to the high number of up-regulated and strongly co-expressed gene such as the 
MCM’s. The most up-regulated gene was SLC26A2, which we previously discussed as up-
regulated as a result of viral integration. The strongest correlations were between MCM7 and 
MCM3, as well as DSN1 and CHEK1. The second cluster was significantly enriched for 
“macrophage colony-stimulating factor signaling pathway” (GO:0038145) due to the presence of 
CSF1R, likely upregulated on chromosome 5 due to viral integration (as discussed above). This 
gene was strongly co-expressed with TCAM1P (testicular cell adhesion molecule 1, pseudogene). 
The remaining three clusters were significantly enriched for cellular division processes. 
Enrichment and up-regulation of these biological processes is consistent with the proliferative and 




Table 2.S4 – Top-ten most significant down-regulated genes in AAE6 compared to NIKS. 
 





CYFIP2 cytoplasmic FMR1 interacting protein 2 0.15 6.92 x 10-21 
AJAP1 adherens junctions associated protein 1 0.14 7.37 x 10-19 
CSMD3 CUB and Sushi multiple domains 3 0.21 4.19 x 10-15 
ANTXR2 anthrax toxin receptor 2 0.31 1.74 x 10-12 
EFNB3 ephrin-B3 0.22 2.46 x 10-12 
SDK2 sidekick cell adhesion molecule 2 0.16 5.97 x 10-12 
SMTN smoothelin 0.35 2.92 x 10-11 
EDA2R ectodysplasin A2 receptor 0.19 2.94 x 10-11 
POU2F3 POU class 2 homeobox 3 0.28 1.84 x 10-10 













SLC26A2 solute carrier family 26 (anion exchanger), member 2 114.19 2.14 x 10-173 
CSF1R colony stimulating factor 1 receptor 407.82 4.70 x 10-112 
GPAT2 glycerol-3-phosphate acyltransferase 2, mitochondrial 387.18 4.76 x 10-80 
IFITM1 interferon induced transmembrane protein 1 9.98 7.56 x 10-45 
MCM2 minichromosome maintenance complex component 2 6.25 4.95 x 10-34 
MEST mesoderm specific transcript 14.63 5.97 x 10-33 
CDCA7 cell division cycle associated 7 6.40 1.21 x 10-32 
RMI2 RecQ mediated genome instability 2 8.80 2.43 x 10-29 
MCM6 minichromosome maintenance complex component 6 4.68 3.23 x 10-24 





Table 2.S6 – Top-ten most significant down-regulated genes in AAE6 compared to EPE6. 
 





EFNB3 ephrin-B3 0.21 3.57 x 10-13 
AJAP1 adherens junctions associated protein 1 0.20 7.32 x 10-13 
CYFIP2 cytoplasmic FMR1 interacting protein 2 0.24 6.01 x 10-12 
PAQR5 
progestin and adipoQ receptor family 
member V 
0.32 6.59 x 10-11 
CSMD3 CUB and Sushi multiple domains 3 0.26 7.60 x 10-11 
DAPK1 death-associated protein kinase 1 0.24 1.02 x 10-10 
ANTXR2 anthrax toxin receptor 2 0.36 9.30 x 10-10 
SMTN smoothelin 0.40 5.63 x 10-09 
LOC100216001 
long intergenic non-protein coding RNA 
704 
0.22 9.07 x 10-08 














solute carrier family 26 (anion exchanger), 
member 2 
118.42 1.98 x 10-173 
CSF1R colony stimulating factor 1 receptor 551.09 1.28 x 10-113 
GPAT2 
glycerol-3-phosphate acyltransferase 2, 
mitochondrial 
290.62 6.59 x 10-78 
IFITM1 interferon induced transmembrane protein 1 6.95 7.74 x 10-34 
MCM2 
minichromosome maintenance complex 
component 2 
5.20 4.83 x 10-28 
CDCA7 cell division cycle associated 7 5.25 2.40 x 10-26 
RMI2 RecQ mediated genome instability 2 5.84 1.18 x 10-20 
MEST mesoderm specific transcript 7.06 1.19 x 10-20 
LOC254559 long intergenic non-protein coding RNA 925 12.34 2.50 x 10-20 




2.7.5 – Additional file 5: GO output 
Significantly enriched GO terms (biological processes) for NIKS and AAE6 contrast as 




2.7.6 – Additional file 6: Pearson correlations 
Pearson correlation coefficients for gene-gene pairwise comparisons of down- and up-






CHAPTER 3A – EPITHELIAL ORGANOID MODEL 
This chapter was accepted for publication as a commentary article in Philosophical 
Transactions of the Royal Society B: Biological Sciences on 27 Nov 2018 in the special theme 
issue Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses (“Tissue 
models” section; DOI: 10.1098/rstb.2018.0288) [Jackson et al., 2019]. It has been adapted with 
permission for re-use within this dissertation (non-commercial purpose), as per the Royal Society’s 
2018 Licence to Publish document. 
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3A.1 – Abstract 
 Persistent infection with oncogenic human papillomavirus (HPV) may lead to cancer in 
mucosal and skin tissue. Consequently, HPV must have developed strategies to escape host 
immune surveillance. Nevertheless, most HPV infections are cleared by the infected host. Our 
laboratory investigates Langerhans cells (LCs), acting at the interface between innate and adaptive 
immunity. We hypothesize that this first line of defence is vital for potential HPV elimination. As 
an alternative to animal models, we use smaller-scale epithelial organoids grown from human 
primary keratinocytes derived from various anatomical sites. This approach is amenable to large 
sample sizes—an essential aspect for scientific rigour and statistical power. To evaluate LCs 
phenotypically and molecularly during the viral life cycle and onset of carcinogenesis, we have 
included an engineered myeloid cell line with the ability to acquire an LC phenotype. This model 
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is accurately tailored for the crucial time-window of early virus elimination in a complex organism 
and will shed more light on our long-standing research question of how naturally-occurring HPV 
variants influence disease development. It may also be applied to other microorganism-host 
interaction research or enquiries of epithelium immunobiology. Finally, our continuously-updated 
pathogen-host analysis tool enables state-of-the-art bioinformatics analyses of next-generation 
sequencing data. 
 
3A.2 – Introduction 
 Since the late 1970's, there has been an evolution of growing human keratinocytes in a 
three-dimensional (3D) rather than 2D manner for “the reconstitution of living skin” [Bell et al., 
1983] in a cell culture dish with nomenclatures such as “organotypic culture” [Merrick et al., 
1992], “keratinocyte raft cultures” [Southern et al., 2001], “organotypic raft cultures” [Anacker 
and Moody, 2012], or most recently skin “organoids” [Fatehullah et al., 2016] [Figure 3A.1]. 
Initially, the main driver for in vitro skin cultivation was grafting. To grow keratinocytes as 
stratified epithelium was first reported by Rheinwald and Green [Rheinwald and Green, 1975], 
followed by Bell’s “full thickness skin equivalent” [Bell et al., 1979; 1981; 1983]. In the early 
1990's primary keratinocytes infected with high-risk (HR) human papillomavirus (HPV) were 
found to have premalignant characteristics in organotypic culture [Blanton et al., 1991] and various 
models capable of reproducing the HPV infectious cycle were established by several independent 
groups [Dollard et al., 1992; Meyers et al., 1992; Flores et al., 1999]. Globally, HPV—a DNA 
virus, is the most common sexually transmitted infectious agent with an ~10% prevalence in 
healthy women [Crow, 2012] and more than 300 types identified to date (the majority of the 500+ 
types of human and non-human PVs identified [Van Doorslaer et al., 2017a], based on the 
Papillomavirus Episteme, PaVE: https://pave.niaid.nih.gov [Van Doorslaer et al., 2013; 2017b]). 
A subset of 12 HR types, with HPV16 being the most common, cause cancer (e.g. oropharyngeal 
and gynaecological) in humans [Bouvard et al., 2009; Crow, 2012]. The malignant potential of 
HR HPVs is largely due to the E6 and E7 oncogenes encoding their corresponding proteins which 
interfere with cellular integrity [Hoppe-Seyler et al., 2018 and references therein]. HPV16 variants 
implicated in a higher risk for cervical cancer [Zehbe et al., 1998b] showed a higher degree of 
dysplasia in 3D raft cultures compared to lower risk variants [Richard et al., 2010; Jackson et al., 
2014; 2016]. The next generation of rafts included immune components to study the role (or lack 
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thereof) of innate and adaptive immunity in combatting HPV. For instance, models including 
lymphocyte infiltration [Jacobs et al., 1998] and the microenvironment of Langerhans cells (LCs) 
[Hubert et al., 1999]—epithelium-specific dendritic cells (DCs), were developed. More recently, 
a bone marrow-derived cell line called MUTZ-3 [Masterson et al., 2002] has been used to produce 
DCs and LCs [Kosten et al., 2015b]. Such a cell line allows far better reproducibility in a research 
context where many biological replicates are necessary for robust research results with high 
statistical power. 
HR HPV such as type 16 is the main risk factor for cervical cancer provided it can persist 
in the host [zur Hausen, 2002]. Variant designations are based on their geographical region of 
origin [Mirabello et al., 2018 and references therein]. The European Prototype (EP) was the first 
HPV16 genome published more than 30 years ago [Seedorf et al., 1985] and at present, four 
(formerly five) lineages are known: A (European sub-lineages A1-A3 and Asian sub-lineage A4), 
B (African-1 sub-lineages B1-B4), C (African-2 sub-lineages C1-C4), and D (North American 
sub-lineages D1 and D4, and Asian-American sub-lineages D2 and D3) [de Araujo Souza et al., 
2009; Burk et al., 2013; Mirabello et al., 2018]. Recently, we have put our efforts on the common 
EP and AA variants which differ in only 3 amino acid changes at residues 14 (Q>H), 78 (H>Y) 
and 83 (L>V) in the major transforming protein E6 [Richard et al., 2010; Niccoli et al., 2012; 
Jackson et al., 2014; 2016; Cuninghame et al., 2017]. Epidemiological studies revealed that the 
AAE6 variant is a higher risk factor for dysplasia as well as an earlier onset of invasive tumours 
than EPE6 [Xi et al., 1997; Berumen et al., 2001]. AAE6 has a greater transforming, migratory, 
and invasive potential than EPE6 when retrovirally transduced into primary human keratinocytes 
during recent long-term in vitro immortalization studies [Richard et al., 2010; Niccoli et al., 2012]. 
Further, AAE6 is more prone to integrate into the host cell genome [Jackson et al., 2016] and 
demonstrated an altered metabolic phenotype reminiscent of the Warburg effect [Cuninghame et 
al., 2017]. These results suggest that coding changes in E6 have strong mechanistic and functional 
consequences for infection and thus contribute to marked differences in cancer risk. 
To decipher the fundamental biology of HPVs and their tumourigenic features in a model 
system, the organotypic 3D infection model (raft culture, or organoid, the latter will be used 
henceforth) has the advantage of allowing reproducible and simultaneous epithelial differentiation 
and therefore the occurrence of an active viral life cycle. Our approach is a joint venture between 
the biological, clinical, and computer sciences, with like implications for clinical and basic 
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research. In addition to how E6 variants are implicated in the development of HPV-related 
diseases, this model has been developed to adapt to new enquiries regarding how the early cell-
based innate immune system fights a common virus such as HPV.  Here, we discuss an organoid 
epithelial model drawing on previous research and experience by us [Richard et al., 2010; Jackson 
et al., 2014; 2016] and others [Rheinwald and Green, 1975; Bell et al., 1979; 1981; 1983; Blanton 
et al., 1991; Dollard et al., 1992; Merrick et al., 1992; Meyers et al., 1992; Jacobs et al., 1998; 
Flores et al., 1999; Hubert et al., 1999; Southern et al., 2001; Masterson et al., 2002; Anacker and 
Moody, 2012; Kosten et al., 2015b; Fatehullah et al., 2016]. Its strength lies in the unique 
combination of components essential for our application: primary, HPV-permissive host cells from 
various anatomical sites, the recapitulation of the HPV infectious cycle using full-length HPV16 
genomes, naturally existing HPV16 variants throughout its genome, controllable copy numbers of 
HPV-positive keratinocytes, tissue-residing LCs, phenotypical and immunological 





Figure 3A.1 – Historical overview of epithelial models. Significant developments in the 
evolution of three-dimensional epithelial models (focusing on the incorporation of Langerhans 
cells and HPV16 variant research) in the last four decades are depicted along with potential future 
directions. Due to space constraints we are unfortunately unable to showcase all the excellent 




3A.3 – The “Silent Killer”: How HPV Evades Host Immune Recognition 
 HPV, the “silent killer", is a master in evading the host immune response, causing illness 
and in some cases death of the infected host. The Indigenous, supernatural monster Windigo comes 
to mind serving as a metaphor when our group explained the danger of HPV to First Nations 
women in Northwest Ontario, Canada [Zehbe et al., 2016b]. Here, we outline an eclectic, 
experimental approach appropriate to study HPV infection. We will employ healthy mucosal or 
skin tissue including epidermis and dermis either from the uterine cervix (non-keratinizing, 
cervical keratinocytes), the oropharyngeal area (non-keratinizing, gingival keratinocytes) or the 
skin (keratinizing epithelial keratinocytes) with matching fibroblasts. Fortunately, these cells can 
now be bought, avoiding the barrier of lengthy procurement processes [Villa et al., 2018]. 
Epidermis on its own or combined with dermis models are also commercially available. However, 
our context precludes the use of such models since donor background cannot be controlled and to 
“infect” with HPV, we need to grow 3D cultures to allow the viral life cycle to take place for the 
production of infection-competent virions. Our lab has the necessary experience with organoids, 
as we can rely on a decade or so of in-house experience in 3D culturing [Zehbe et al., 2009; Richard 
et al., 2010; Niccoli et al., 2012; Jackson et al., 2014; 2016; Villa et al., 2018]. 
 Under normal physiological conditions, infiltrating T-cells from the underlying blood 
vessels migrating into the dermis and even the epidermis has not been observed. However, 
immature and mature LCs belong to the normal mucosa and skin landscape and hence only their 
integration in our current model has been considered. Rodrigues Neves & Gibbs [2018] pointed 
out that a 3D keratinocyte model with both immune components is still lacking in the scientific 
literature. This is clearly a draw-back when researching various allergens where inflammation is 
the biggest obstacle to tackle. However, in the context of persistent HPV in immune-comprised 
organs such as the cervix, the sheer lack of these components may provide major viral immune 
evasion strategies to escape host immune surveillance. Indeed, HPV is thought to keep a low 
inflammatory profile—meaning that immune cells are not attracted to the site. Without causing 
epithelial inflammation, HPV has developed many strategies to go undetected, both during innate 





3A.3.1 – The HPV clearance hypothesis: the role of LCs 
 LCs are a distinct DC subset comprising about 2–3% of epidermal cells [Kissenpfennig 
and Malissen, 2006] that are at the interface between innate and adaptive immunity. They reside 
in the supra-basal part of the epithelium and their adhesion is mediated by E-cadherin [Tang et al., 
1993]. Keratinocytes are important for LC activation and maturation as they modulate immunity 
through their production of chemokines and pro-inflammatory cytokines. We hypothesize that in 
hosts clearing their HPV infection (the majority) [Stanley, 2012], keratinocytes stimulate LC 
activation, e.g. via TNF-α and TGF-β secretion which promotes LC migration from the epidermis 
to dermis and lymph nodes. Melief [2005] depicts such a scenario where “danger signals” and 
“activated dendritic cells” lead to the activation of cytotoxic T-cells—the first step towards tumour 
elimination. While we generally agree with this notion, further details were added to illustrate our 
model and adapt it to the viral infectious cycle and early carcinogenesis [Figure 3A.2]. 
LCs are patrolling antigen-presenting cells (APCs) acting as immunological sentinels in 
mucosal and skin tissues. They likely engulf and phagocytose viral particles and/or dead HPV+ 
keratinocytes before a lesion develops and may be the first encounter of an infected host to fight 
an HPV infection. In turn, keratinocytes secrete pro-inflammatory cytokines and dermal fibroblasts 
secrete chemokines/chemo-attractants, helping LCs to mature and migrate to lymph nodes for 
cross-presenting HPV peptides to CD4+ and CD8+ T-cells. LCs, however, seem to be less frequent 
in the transformation zone [Deligeoroglou et al., 2013] where most cervical cancers develop, and 
E6 negatively interferes not only with E-cadherin but also with the expression of LC chemo-
attractants [Iijima et al., 2013 and references therein]. It is this phase of the immune system that 
we think is one of the key interfaces between pathogen and host, and which the virus must escape 
to persist in its host. Interestingly, the oncoprotein E6 of HPV16 down-regulates E-cadherin 
[Matthews et al., 2003; Togtema et al., 2015; references therein], and an E6 variant with only one 
amino acid change of AA at residue 83, showed this to be increased compared to EP [Togtema et 
al., 2015]. This, and the potential role of LCs in HPV clearance, prompted us to investigate LC 






Figure 3A.2 – Epithelial microenvironment and immune landscape. HPVs infect epithelial 
tissues lining the upper digestive or genital tract most likely by infecting the stem cells of the 
proliferating basal layer. If the viral genome persists in the basal layer, then it can be amplified in 
the differentiating layers. Thereafter new virions are released without causing an inflammation. 
Langerhans cells (LCs) reside in the epithelia as immunosurveillance cells. Many parameters 
(markers) to investigate LC patterns of activation, differentiation and migration from epidermis to 
dermis (and potentially to draining lymph nodes) are known. They will be closely investigated in 
the depicted model in the context of the two HPV variants under study. Viral life cycle will be 
confirmed, e.g. with viral capsid proteins L1/L2. The epithelial phenotype will be assessed via 
appropriate keratin (K) markers in the various anatomical sites, e.g. K5/10 in skin, and keratinocyte 
immune markers for an environment commensal for LC epidermis to dermis migration, e.g. MHC 
I/II, E-cadherin, TNF-α, and TGF-β. We will further test markers of epidermal LCs, e.g. MHC II, 
CD11c, CD207 (langerin), EpCAM and markers of LC migration ability, e.g. MHC II, CD28, 
CD40, and CXCR4 and CCR7 for a 2-step migration. The above markers will all be tested in situ 
by immunofluorescence. Monitoring early HPV infection by the host needs danger signals 
(cytokines and chemokines) to attract LCs traveling to sentinel lymph nodes. Such LC attractants, 
e.g. CCL2/5/20, and CXCL12 (fibroblast-derived) and CCL27/28, IL-18 and type I IFNs (KC-
derived) will be characterized via supernatant. In collaboration with the Alizon group in 
Montpellier, we use mathematical models to discover novelties/unknowns, test new hypotheses 
and research questions in silico [Murall et al., 2019]. 
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3A.3.2 – Implication of HPV16 variants in modulating the host immune system 
In the past decennium and outlined in the introduction, our lab has provided ample evidence 
that E6 variants within the HPV16 genome strongly promote functional changes in the mammalian 
host. More recently, we discovered that the highly oncogenic AAE6 variant may also be involved 
in immune escape like the L83V variant [see 3A.3.1 – The HPV clearance hypothesis: the role of 
LCs]. In our given context, other than promoting the differentiation of LCs, and in contrast to 
keratinocytes, TGF-β stimulates stromal fibroblasts to proliferate and to synthesize matrix proteins 
[Buschke et al., 2011]. An interesting finding from the Jackson et al. [2016] RNA-seq data is worth 
exploring further: in addition to one of the significantly down-regulated clusters of genes being 
involved in the "negative regulation by host of viral transcription", we also found that the TGF-β 
innate immune pathway signature seems to be down-regulated in the AAE6 but not in the EPE6 
organoids. This is intriguing since TGF-β is the key cytokine for LC maturation. TGF-β was 
expressed ~1/3 lower in AAE6 vs HPV-negative and EPE6-containing organoids. Although this 
is not significant when considering the differential expression results which use a conservative 
filtering technique (given the high-throughput nature), the similarly listed “TGF-β induced” 
(TGFBI) is significantly lower. TGFBI, an extra-cellular matrix protein, promotes inflammation, 
integrin-mediated monocyte adhesion, migration and chemotaxis [Kim and Kim, 2008]. TGFBI 
down-regulation by AAE6 may be a means to further tone down inflammation in the HPV 
environment. Moreover, innate immune receptor signalling [Li et al., 2016] may also be affected 
by the AAE6 variant. In a recent protein-protein interaction screen, we found that AAE6 but not 
EPE6 binds to various E3 ligases (other than E6AP) indicating that innate immune-regulated 
transcription factors (e.g. NF-kβ and IRF7) as well as anti-microbial peptides (e.g. defensins and 
cathelicidins) and pro-inflammatory cytokines (e.g. IL-1β) may be down-regulated [Mehran 
Masoom, unpublished observations]. Lastly, our finding that AAE6 interferes with host cell 
metabolism by shifting to a Warburg effect [Cuninghame et al., 2017] has also been looked at 
from the perspective of tumour-associated macrophages (TAMs) in the stroma [Colegio et al., 
2014]. Interestingly, it was reported that tumour-derived lactic acid caused the M2-like 
polarization in TAMs. Altogether, we conclude that in an immunological context, the AAE6 





3A.4 – An Eclectic Methodological Approach for an Epithelial Organoid 
We will perform systematic organotypic epithelial culturing [Jackson et al., 2014; 2016] 
in a step-wise manner through three primary experimental phases: Preparation, Cultivation, and 
Characterization. The first phase provides a foundation focused on a priori experimental design 
for reproducibly answering biological questions in a “life-like” model of human epithelium. The 
second phase continues with the process of growing [Figure 3A.3] and harvesting these lab-grown 
tissues. Finally, the third phase concludes with thoroughly characterizing the tissues via biological 
analysis and interpretation. While additional components and complexities (e.g. beyond LCs) 
could be included in an organoid model to make it ever more “life-like”, we strive to present a 
simplistic yet useful approach with a focus on studying HPV biology (and specifically, the 
molecular underpinnings of increased tumourigenic risk due to viral variants, such as via LC 
interactions). The overall objective is to establish an immune-competent 3D in vitro organoid to 
study two commonly found HPV16 E6 variants undergoing their active HPV life cycle. We will 
determine an initial host-pathogen interaction, i.e. the suppression by HPV at the innate immunity 
level—for which the life cycle needs to be activated. Our previous model, even without LCs, 
fulfilled closely the needs of in vivo but prevented us from controlling the number of HPV+ cells 
after transfection [Jackson et al., 2014; 2016]. The new model, on the other hand, can be adapted 






Figure 3A.3 – Flow diagram of the epithelial model. To culture immunocompetent organoids: 
on day 1, in a 24-well plate, fibroblasts are embedded in a collagen matrix as a dermal equivalent 
that supports keratinocyte growth. On day 2, keratinocytes (containing HPV episomes) and 
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Langerhans cells are seeded on top of the dermal equivalent at a ratio of 1:1. On day 3, the rafts 
are lifted and transferred to a 6-well plate with a membrane insert to create an air liquid interface 
exposing only the dermal equivalent to media. Subsequently, the rafts are fed for two weeks with 
a media change every second day. This environment encourages differentiation and stratification. 
With our experimental model, we strive to mimic what happens in vivo. With this model, the viral 
life cycle can be propagated, and this is only possible when cells are grown in 3 dimensions as 






3A.4.1 – Preparation of the revised model 
 Here, we will use the entire HPV16 AA variant genome’s SNPs (i.e. altogether ~150 not 
just the 3 SNPs within the E6 gene as done previously) [Jackson et al., 2014; 2016]. Using the 
Cre-Lox recombination system [Lee et al., 2004; Wang et al., 2009] with subsequent selection 
potentially all transfected cells will carry the full HPV16 genome, which allows us to control the 
number of HPV+ cells within the 3D tissue. An alternative approach will also be used to increase 
DNA transfection efficiency three-fold, i.e. from ~10% using chemical transfection to ~30% with 
electroporation [Potter and Heller, 2003] prior to selection. We have found a way to create smaller 
3D cultures enabling us to have more biological replicates. This will increase the effect and sample 
size for more robust and reliable statistics. For LCs, we will use the MUTZ-3 cell line [Masterson 
et al., 2002] as this allows experimental reproducibility and avoids donor variability when using 
DCs derived from peripheral blood monocytes [Chau et al., 2013]. We performed experiments to 
assess the suitability of this line using flow cytometry to identify a “differentiated”, double positive 
population (langerin/CD1a) [Figure 3A.4a,b]. Another group has used this approach successively, 
albeit in a context of skin allergens and irritants [Kosten et al., 2015b]. 
The first step of our epithelial organoid approach will be to prepare the experimental model 
by carefully designing experiments with the research question at the forefront. This includes first 
establishing the hypotheses to be tested, defining the experimental variables (dependent and 
independent), and performing sample size estimations through power calculations based on 
expected effect size and variability (which can be informed via previous work or preliminary 
"pathfinder" experiments). Biostatistics are one facet of our eclectic approach, and while under-
represented in past literature, may be applied to help resolve reproducibility concerns in cancer 
biology. When estimating sample sizes to appropriately test hypotheses, the concept of “biological 
independence” is important to consider. While truly independent replicates would be altogether 
uniquely derived biological samples (such as different donor individuals), it can be helpful to think 
of biological independence as a spectrum ranging from these uniquely derived specimens on one 
end, to increasingly more feasible options, albeit with a proportional loss in true biological 
independence. For epithelial cultures, we suggest that the "level of interrogation" should be the 
main consideration when determining the level of biological independence required. For example, 
with our research question focused on viral variants and their differential tumourigenic risk to the 
host, the level of interrogation would be at the interface between virus and host, such as the 
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introduction of viral genomes into keratinocytes via transfection (chemical or physical). So long 
as the research question is focused on the difference between the viral variants, a simple yet 
effective design would be to replicate the experiment with independent transfections using the 
same donor pool of cells (controlling this background if possible, to some extent, given inherent 
variability in passaging cells over time). If the research question was broader, by including 
donor/host variability, then the level of interrogation would correspondingly be at the host-level, 
requiring unique donors such as via patient-derived samples [Villa et al., 2018]. Once the 
experimental design has been established, the next stage of the approach is to perform material 
calculations and establish the organoid cultivation time-course. 
This includes growing the required host cells (in a humidified incubator at 37°C and 5% 
CO2) either with the intention of incorporating into organotypic epithelia (such as keratinocytes, 
fibroblasts, and Langerhans cells differentiated from the MUTZ-3 myeloid leukaemia cells), or in 
support of those cells (such as 5637 bladder carcinoma cells and J2/3T3 mouse embryonic 
fibroblasts). While these cells vary in their media requirements, adherence (monolayer vs 
suspension cultures for the immune cells), and culture technique, an important consideration is the 
tissue origin and donor-background of the cells used, and whether they are primary or 
immortalized, and whether they will be matched for an experiment (e.g. gingival fibroblasts with 
gingival keratinocytes to model the oral epithelia). We have tried near-diploid immortalized 
keratinocytes (NIKS, [Allen-Hoffmann et al., 2000]), primary human foreskin/epidermal 
keratinocytes (PHFKs or HEKs) and primary human oral/gingival keratinocytes (HGKs). Also, 
we have generated epithelial organoids from patient-derived cervical biopsies (via suspected 
lesions at colposcopy, [Villa et al., 2018]). Primary cervical cells (both keratinocytes and 
fibroblasts from the uterine cervix) are now commercially available. The decision on which cells 
to use may be relevant due to tissue region susceptibility differences [Deng et al., 2018], tissue 
microenvironments, and variations in signalling affecting differentiation and possibly the viral life 
cycle and immune environment. Components of the dermal equivalent (typically collagen and 
fibroblasts), making up the extra-cellular matrix (ECM) may also be relevant factors. 
Finally, beyond the host components, the sourcing and preparation of the viral genomes is 
at the crux of our experimental design and research question. Viral genomes have previously been 
from isolates, where a small number of modifications (e.g. in the E6 gene) can be introduced via 
mutagenesis, but now it is also possible to synthesize whole genomes, including all desired SNPs, 
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or intentional modifications/deletions, based on reference genomes. Using gene synthesis and 
cloning, it is also possible to introduce LoxP sites which are useful for Cre-LoxP-mediated 
transfections as a method of introducing viral genomes along with selection genes into host 
keratinocytes [Figure 3A.4c]. Using this technique, we performed a proof of principle study where 
we achieved an active viral life cycle using synthesized HPV16 EP whole genomes with LoxP 
sites in the SphI restriction site (previously used by others [Lee et al., 2004; Wang et al., 2009]) 
as well the alternatively chosen PmlI site (with a previously unknown effect on the viral life cycle), 
further upstream in the upper regulatory region (URR) and outside of potential transcription factor 
binding sites [Figure 3A.4d]. Synthesized HPV16 EP whole genomes both yielded an active life 






Figure 3A.4 – Characterization of the epithelial model. Langerhans cells (LCs) can be derived 
from MUTZ-3 cells via a cytokine-mediated differentiation over approximately 10 days [a]. 
Morphologically they appear more irregular and clustered together than their progenitors and 
differentiation success can be verified via flow cytometry for cell-surface markers CD1a and 
CD207 (langerin) as well as immunofluorescence for CD207 [b] and adhesion molecule E-
cadherin. In addition to LCs, a major focus of our research is to study HPV16 genome variants, 
using full-genomes which contain all naturally-occurring polymorphisms, and to introduce these 
into our epithelial model. In this example case, near-diploid immortalized keratinocytes (NIKS, 
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[Allen-Hoffmann et al., 2000]) are co-transfected with LoxP-flanked HPV genomes and a Cre-
recombinase expression plasmid to yield selected populations of keratinocytes containing viral 
DNA [c] and able to undergo a viral life cycle when grown as epithelial organoids (evidenced by 
capsid protein production, L2). As well, epithelium can be further characterized for proliferation 
markers (such as Ki-67) and cell-cycle dysregulation markers due to E7 expression (p16INK4A) [d]. 
European Prototype (EP) genomes were designed to contain a LoxP site in either the SphI or PmlI 





3A.4.2 – Organoid cultivation and characterization 
 While many past studies have focused on the cultivation of epithelial organoids [Figure 
3A.1], including detailed methodology papers that serve as a good foundation and provide more 
thorough descriptions of the process, as well as video tutorials [Anacker and Moody, 2012], it will 
now be important to expand the perspective to different experimental design considerations (such 
as multi-component rafts) and a variety of end-points and time-courses. Recently, novel methods 
for studying the HPV life cycle have been described elsewhere [Bienkowska-Haba et al., 2018]. 
Different size organoids can be grown, and we have tried small (96-well sized), medium 
(48-well sized), and large (24-well sized) rafts, where smaller rafts allow for increased sample size 
for a variety of downstream applications. While being cost effective (with the exception of plate 
inserts and per sample materials), there is increased difficulty manually handling smaller rafts and 
the extraction yields of tissues are lower. Hence, we settled for medium-sized rafts as an optimal 
balance. As well, different amounts of fibroblasts can be seeded into the dermal equivalent, where 
we have found that an increased number helps with epithelial differentiation. Varying the number 
of infected cells within the epithelium could be a way to model varying stages of disease, from 
low-grade to high-grade lesions (where higher-grade lesions have a greater number of HPV+ cells 
[Algeciras-Schimnich et al., 2007]). 
The duration of culturing (typically 1 to 21 days) can be assessed using time-series rafts, 
as we have done previously to aid in mathematical modelling [Murall et al., 2019]. While 14 days 
is typically used as the peak of the viral life cycle, shorter or longer durations (to a limited extent) 
may be relevant for assessing changes over time as well as the interaction between differentiation 
and viral replication, genome amplification, and transcription as they relate to persistence and 
integration. Prior to harvesting (typically <24 hours before), the thymidine analogue BrdU can be 
added to culture media to assess proliferation (where suprabasal proliferation is indicative of 
keratinocytes infected with HPV). When culturing and harvesting, biosafety precautions are 
required (e.g. biosafety level II in Canada), as active viral particles may be produced. Harvesting 
can be done to preserve structure, via fixation (e.g. formalin), or through tissue dissection (e.g. 
manual separation of the epidermis from dermis) followed by homogenization of the relevant 
compartment and molecular extractions (e.g. DNA, RNA, protein), or processing for single-cell 
suspensions. For formalin-fixed and paraffin-embedded tissues, typical histological assessment is 
performed using Haematoxylin & Eosin staining, whereas in situ techniques such as 
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immunohistochemistry and immunofluorescence can be used for qualitative and semi-quantitative 
characterization of host markers (e.g. Ki-67 proliferation marker, BrdU-incorporation proliferation 
marker, p16INK4A cell cycle dysregulation and surrogate E7 marker, cytokeratin 5 and 10 
differentiation pattern markers, and viral markers (L1 and L2 capsid proteins)). Data and statistical 
analysis can be performed using open-source software. Extracted and purified molecules, such as 
nucleic acids (DNA or RNA), can be used for common assays such as viral copy number or 
viral/host gene expression or used for more high-throughput techniques such as microarray or 
NGS. 
 
3A.4.3 – Immune-competent component 
 The feasibility of incorporating MUTZ-3-derived LCs into 3D epithelial cultures has been 
reported previously by the Gibbs group [Rodrigues Neves and Gibbs, 2018]. While LCs normally 
make up ~2-3% of the epithelium, this group used a ratio of 1:1 or even 2:1 in 3D cultures 
compared to the number of keratinocytes. This high number was deemed necessary because only 
a subset of cytokine-treated MUTZ-3 cells differentiate to double-positive langerin/CD1a LCs: 
e.g. 30-70% (S.W. Spiekstra, Gibbs group, personal communication) or even lower at 10-20% in 
our hands. Moreover, a proportion of differentiated LCs die or do not attach. Nevertheless, in our 
preliminary results from monolayer attachability experiments with half, equal or double ratios of 
cytokine-differentiated LCs versus keratinocytes, we yielded similar proportions of attached LCs 
(average of ~13%). The efficacy may be less in a 3D scenario due to LCs maturing and migrating 
out of the epithelium too soon. Instead of compensating this loss with an increased ratio of LCs, 
our populations will be further enriched for an increased number of differentiated LCs using anti-
langerin conjugated microbeads. The starting population before differentiation will also have to be 
monitored carefully so that CD14+ and CD34+ proportions are close to equal [Santegoets et al., 
2006]. Likewise, timely LC maturation, which should be triggered by cytokine production of 
surrounding keratinocytes and chemokines from dermal fibroblasts will have to be considered. LC 
maturation may not happen through these “natural” means and instead require a cytokine boost, 
e.g. of TNF-α and IL-1β and prostaglandin E2, or an allergen or irritant [Kosten et al., 2016].  
So far, the outlined LC incorporation approach only allows a qualitative assessment of LC 
characteristics in the tissue. Hence, a quantitative assay is also needed for our research question to 
detect any measurable effect between the two variants under study. Therefore, we will use a 
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modified transwell migration assay adding artificial extracellular matrix (ECM) on top of the upper 
transwell membrane before adding various ratios of LCs and keratinocytes and delay LC 
maturation for at least two days to measure any effect due to HPV. Fibroblasts will be seeded into 
the underlying well. With this system, cell chemotaxis of LCs can be measured like in or ex vivo. 
Because the transfected HPV+ cells are not yet expected to be tumourigenic, only a few will 
spontaneously pass through the ECM but LCs are expected to do so if they receive the appropriate 
signals to “mature” from keratinocytes and fibroblasts. 
Finally, it is tempting to use two different methods in parallel: to include LCs in one and 
omit them altogether in the other. Indeed, even without LCs, we can still test keratinocytes and 
fibroblasts for markers that render a milieu suitable for LC migration from epidermis to dermis 
[summarized in Kosten et al., 2015a]. Consequently, both approaches will be attempted using 
immunofluorescence and bead-based multiplex assays to detect immunological markers (or lack 
thereof) in keratinocytes and culture supernatant. 
 
3A.4.4 – NGS and the Pathogen-Host Analysis Tool (PHAT) 
 NGS of extracted nucleic acids (DNA and RNA) allows for a comprehensive analysis of 
the molecular background of our organoids and the ability to determine differences in HPV16 
variant interactions with host tissue [Jackson et al., 2016]. Important considerations include library 
preparation (whether or not a sequence capture or enrichment step will be used to enrich the low 
abundance viral sequences relative to the host), sequencing (platform used, short vs long reads, 
read depth anticipated), as well as bioinformatics analysis pipelines to be used (custom-scripts, 
high-performance computing cluster access, or desktop tools). Ultimately, next-generation or 
high-throughput sequencing (HTS) analysis can enable hypothesis-testing as well as hypothesis-
generation via exploration, and possibly spur future research questions and additional cycles of 
organoid culturing. 
To aid researchers with these data, we developed a platform to analyse pathogen-host 
relationships in next-generation sequencing data by using industry standard methods while 
reducing barrier to entry (https://github.com/chgibb/PHAT, [Gibb et al., 2019]). For the PHAT 
"toolbar", or graphical user interface (GUI), obtained sequence data is added (Input), quality-
controlled (QC) and aligned with the appropriate reference sequence; this platform gives the user 
access to the alignment summary of obtained NGS data (DNA and/or RNA-seq) compared to a 
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pathogen or host reference sequence. Number and percentage of reads that have aligned to the 
reference are provided, and the user has access to an interactive (scrolling and zooming) linear 
visualization of viral reads and coverage across a reference genome, which also highlights single-
nucleotide polymorphisms (SNPs) that are within reads, compared to the reference, that can be 
helpful for pathogen genotyping. The Output button gives access to customizable data tables that 
can be output and saved in preferred spreadsheet format (such as .csv or Excel) for use in other 
software or for publication/reports. This allows the user to select exactly which samples and 
columns of data they would like to output, such as quality control information, alignment statistics, 
SNPs/genotyping, etc. The Genome Builder is a tool within PHAT that can be used to create 
circular visualizations of pathogen reference genomes (rather than just linear maps for the round 
HPV plasmids). Viral genes, SNPs within the genes, and circular read coverage (which is 
important for assessing episomal/integrated forms in the case of HPV) can be added and annotated. 
We recently added the ability to work with pre-aligned data from large datasets, where users can 
take output from high-performance computing clusters and work with it on their desktop or laptop 
computer, and we are currently adding enhanced viral integration detection features (given one of 
our most pertinent research questions is the pattern of viral integration into host DNA between 
HPV16 variants). Overall, PHAT is under continued development and users are automatically 
notified of any updates, which can then be downloaded and installed seamlessly. 
 
3A.5 – Limitations of Existing Research Models 
 While we advocate for a simple yet useful model of human epithelium, we appreciate that 
achieving this goal has limitations. George E. P. Box’s wisdom on model utility can be extended 
to biological models: “Since all models are wrong the scientist cannot obtain a ‘correct’ one by 
excessive elaboration” [Box, 1976]. Hence, avoiding excessive elaboration may be important for 
keeping experiments manageable and focused, but an overly simplistic model may generalize or 
altogether lack essential components or characteristics that are found naturally to provide insight 
for the biological phenomenon studied. Box continues "… following William of Occam, one 
should seek an economical description of natural phenomena. Just as the ability to devise simple 
but evocative models is the signature of the great scientist, over-elaboration and over-
parameterization is often the mark of mediocrity” [Box, 1976]. This limitation can be overcome 
by adapting the model to include only the essential components to answer the actual research 
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question. In this focused approach, we knowingly exclude parts in our organoid model, such as 
lymphoid cells, that eventually may become involved in the host immune process but that currently 
are outside our study frame. With continued advances in high-throughput assays as well as 
computing power and analytics, it may be possible to simulate human epithelia in silico using 
mathematical modelling [Murall et al., 2019]. Such a technique could be a powerful tool in 
combination with biological models to provide dataset training and verification, for answering a 
variety of questions pertaining to epithelial responses (e.g. due to viral infection) and testing 
hypotheses by modulating key parameters. Finally, advances in single-cell sequencing and in situ 
analysis may uncover new information about tissue heterogeneity and molecular signatures during 
a viral life cycle. 
 
3A.6 – Conclusion 
 This commentary describes our concept accurately tailored to the crucial time-window of 
early virus infection, e.g. HPV elimination (or not) in a complex organism such as humans. We 
describe a unique, robust and reproducible alternative to animal models to study HPV immune 
biology during the full viral life cycle. While most other investigations centred around skin, we 
and a select few others [Kosten et al., 2015a; Kosten et al., 2016] also consider anatomical areas 
lined by mucosal tissue mostly affected by HPV: the uterine cervix and the oral cavity. 
Consequently, immune molecules in skin are well characterized [Rodrigues Neves & Gibbs, 2018] 
including a global approach [Spurgeon et al., 2017], while this is still largely lacking for both 
mucosal sites. Most importantly, HPV variants have not been addressed at all. Our approach will 
shed new light on host immune evasion by HPV in the context of HPV variants focusing on HPV 
and its interactions with epithelial LCs. In particular, we investigate the molecular signature of 
LCs surrounding keratinocytes in the epidermis and underlying fibroblasts in the dermis in the 
context of a high-risk HPV, i.e. type 16 and what role HPV variants, differently implicated in 
cervical disease have [Jackson et al., 2014; 2016 and references therein]. Here, for the sake of 
creating a reproducible and complex model to study two common, naturally occurring HPV16 
variants, we do not wish to include genetic variables (in addition to those found in the viral 
genomes under study). However, the outlined model is amenable to be expanded to an 
epidemiologic study with multiple host genome backgrounds involving individual or all three 
anatomical sites with an appropriate sample size. To bear in mind: preparing organoids the way 
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we describe here requires an interdisciplinary mindset, meticulous preparedness coupled with a 
good pair of lab hands, a large portion of patience while maintaining these cultures, and a great 
deal of understanding and appreciation for bioinformatics. The lucky, successful candidate will be 
hugely rewarded with new discoveries. 
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CHAPTER 3B – THEORETICAL APPLICATION OF THE MODEL 
This chapter is an interdisciplinary application of our epithelial organoid model, 
specifically for the study of epithelial stratification and infection dynamics in silico using 
mathematical models. Below are excerpts relevant to this dissertation, focused on my primary 
contributions, from the full-text of a collaborative research article published in PLoS 
Computational Biology on 23 Jan 2019 (DOI: 10.1371/journal.pcbi.1006646, originally pre-
printed in bioRxiv on 10 Dec 2017, DOI: 10.1101/231985) [Murall et al., 2019]. It has been 
adapted with permission from the authors for re-use within this dissertation. 
 
Excerpts from: Epithelial stratification shapes infection dynamics 
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3B.1 – Abstract 
Infections of stratified epithelia contribute to a large group of common diseases, such as 
dermatological conditions and sexually transmitted diseases. To investigate how epithelial 
structure affects infection dynamics, we develop a general ecology-inspired model for stratified 
epithelia. Our model allows us to simulate infections, explore new hypotheses and estimate 
parameters that are difficult to measure with tissue cell cultures. We focus on two contrasting 
75 
 
pathogens: Chlamydia trachomatis and Human papillomaviruses. Using cervicovaginal parameter 
estimates, we find that key infection symptoms can be explained by differential interactions with 
the layers, while clearance and pathogen burden appear to be bottom-up processes. Cell protective 
responses to infections (e.g. mucus trapping) generally lowered pathogen load but there were 
specific effects based on infection strategies. Our modeling approach opens new perspectives for 
3D tissue culture experimental systems of infections and, more generally, for developing and 
testing hypotheses related to infections of stratified epithelia. 
 
3B.1.1 – Author summary 
 Many epithelia are stratified in layers of cells and their infection can result in many 
pathologies, from rashes to cancer. It is important to understand to what extent the epithelial 
structure determines infection dynamics and outcomes. To aid experimental and clinical studies, 
we develop a mathematical model that recreates epithelial and infection dynamics. By applying it 
to a virus, human papillomavirus, and a bacterium, chlamydia, we show that considering 
stratification improves our general understanding of disease patterns. For instance, the duration of 
infection can be driven by the rate at which the stem cells of the epithelium divide. Having a 
general model also allows us to investigate and compare hypotheses. This ecological framework 
can be modified to study specific pathogens or to estimate parameters from data generated in 3D 
skin cell culture experiments. 
 
3B.2 - Introduction 
We address to what extent epithelium dynamics affect infection dynamics and as a result 
determine infection outcomes. First, we introduce a general epithelium model, which we calibrate 
using existing data, as well as original cell culture data from a spontaneously immortalized human 
cell line (NIKS) [Allen-Hoffmann et al., 2000]. With this data we infer parameters that are difficult 
to measure, such as the fraction of symmetric cell divisions. We then ‘infect’ this epithelial model 
with chlamydia, wart-associated HPVs and oncogenic (high-risk, HR) HPVs to investigate how 
protective measures by the epithelium affect infection load and duration, while identifying the 
parameters that control key infection traits. We find that epithelium stratification plays a key role 




3B.3 – Results 
3B.3.1 – Uninfected epithelial dynamics 
 To obtain experimentally relevant parameter estimates, we used our model and the known 
parameters as priors to estimate values using original data from raft cultures of NIKS (Normal 
Immortal KeratinocyteS) cells. The NIKS cell-line grows into a 3D epithelium structure and is 
commonly used as a model of cervicovaginal tissue, though they are known to differ from in vivo 
tissue [Allen-Hoffmann et al., 2000]. Figure 2A and B show an example of NIKS cell growth into 
stratified form. Figure 2C shows the dynamics of the number of basal and suprabasal (non-
keratinized and keratinized) cells, along with the inferred dynamics from the model. 
 
 
Figure 3B.1 – Epithelial cell growth in 3D raft cultures. [a] NIKS grown from a single layer 
over a period of three weeks. Dark pink layer in week 3 consist of cornified cells that accumulate 
on the surface. [b] Immunofluorescence staining: DAPI (blue) is nuclear staining for cell counting 
and BrdU (red) is for identifying cells undergoing division; white dots are added to delineate basal 
lines. [c] Data of NIKS growth over time with model fitting. Shading corresponds to 95% 
prediction interval, assuming the data follows a Poisson distribution. 
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3B.4 – Discussion 
Epithelial infections are a major public health burden, and, in particular, STIs are on the 
rise causing a worldwide concern [Hay et al., 2014; Carmona-Gutierrez et al., 2016; WHO, 2016]. 
Quantitative models, both experimental and mathematical, are essential in developing our 
understanding of these infections. As for systemic (and virulent) infections such as HIV and HCV, 
mathematical models have been developed to predict and analyze the kinetics of epithelial 
infections. Here, we show that to understand the kinetics of epithelial infections, it is essential to 
account for the stratified structure of the epithelium, a property that is absent from most models. 
We illustrated how such a general framework can be combined with 3D cell culture data to estimate 
key parameters and how it can generate relevant insights regarding the course of epithelial 
infections. 
 
3B.4.1 – Dynamical implications of ecological features 
The rate of basal cell proliferation had a strong effect on the homeostasis of both uninfected 
and infected epithelia, which suggests an ecological ‘bottom-up controlled’ system [Lindeman, 
1942; Gruner et al., 2008], analogous to those found in free-living food webs. These bottom-up 
effects are more apparent if we consider that basal cell replication is strongly determined by the 
resources that are available in the basal lamina, such as growth factor. While we did not explicitly 
model the resources of the basal layer (it is implicit in the basal proliferation rates), the growth of 
the cells in the experimental set-up does depend on concentration and temporo-spatial distribution 
of growth factors, impacting epithelial thickness and proliferation rates. Therefore, this ecological 
insight of bottom-up driven systems, could be tested more formally in experimental systems by 
monitoring resource concentrations. 
 
3B.4.2 – Perspectives 
 Finally, opening a dialogue between mathematical modeling and experimental data 
generates new hypotheses to test. One of the clearest illustrations of this is our result that burst size 
differences appear as the most parsimonious explanation to explain symptom differences between 
wart-causing and lesion-causing HPV infections. Technological improvements in clinical and 
experimental techniques also allow us to test more subtle predictions. Testing hypotheses 
generated by the model will allow us to move forward by validating the model assumptions that 
78 
 
are consistent with the data and rejecting the others. This will allow us to increase the model 
complexity and test more elaborate predictions. We hope to inspire experimental studies on 
infections of stratified epithelia to focus more on dynamics and time series approaches (including 
mathematics) to better understand these varied and broadly impacting pathogens. 
 
3B.5 – Materials and Methods 
3B.5.1 – Ethics statement 
The Thunder Bay Regional Health Research Institute’s Biosafety Committee approved all 
research involving NIKS cell line cultures. The NIKS cell line [Allen-Hoffmann et al., 2000] was 
obtained from Dr. Paul Lambert, McArdle Laboratory for Cancer Research, University of 
Wisconsin. 
 
3B.5.2 – Cell culture data 
 Organotypic culture growing techniques used here have already been described in detail 
elsewhere [Jackson et al., 2014; 2016]. Original experiments were performed to obtain time series 
data with sufficient replicates for model fitting. Three independent experiments were performed, 
with rafts harvested at one-week intervals (0, 1, 2, and 3 weeks) starting the day after lifting them 
to an air-liquid interface. From a total of 12 formalin-fixed, paraffin-embedded (FFPE) rafts, 48 
tissue slices were imaged using fluorescence microscopy (DAPI staining for cell nuclei) and 
resulted in 3 Fields of View (FOV) per slice (n = 144). Counts in each FOV were done semi-
automatized using ImageJ cell counting software. 
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CHAPTER 3C – ENHANCING THE MODEL’S BIOLOGICAL RELEVANCE 
 This chapter contains recent progress on enhancing aspects of our epithelial organoid 
model for studying the unique pathogen-host relationships of HPV16 sub-lineages. I begin by 
describing improvements to the experimental viral genomes [3C.1 – Full-Length HPV16 Sub-
Lineage Genomes], followed by methodologies for incorporating them into host cells [3C.2 – 
Strategies for Introducing HPV16 Genomes to Host Keratinocytes], and conclude on our 
continued efforts to model innate immunity, such as including Langerhans cells, in epithelial 
organoids [3C.3 – Adapting the Organoid Model to Study Innate Immunity]. 
 
3C.1 – Full-Length HPV16 Sub-Lineage Genomes 
Studying the viral life cycle of HPV16 in a controlled experimental setting typically 
requires the use of full-length circular viral genomes. Our previous studies on HPV16 sub-lineages 
in an organoid epithelial model used full-length genomes [Jackson et al., 2014; 2016; see 
CHAPTER 2], but did not include all EP (A1) and AA (D2 or D3) variations across the whole 
viral genome. Rather, these were based on a mutagenized HPV16 W12E genome [GenBank # 
AF125673], as a common genetic backbone, to isolate the effects of only the non-synonymous 
variant SNPs in the E6 gene. Beyond E6, there may be relevant SNPs in other genes and genomic 
regions [see Figure 3C.1] such as E2 (with 23 SNPs), which regulates E6 expression via cis-
binding to the non-coding viral upper regulatory region (URR, with 15 SNPs of its own) [Hubert 
et al., 2005; Lace et al., 2009]. To address this limitation, we have sought full-length HPV16 sub-
lineage genomes (A1, D2, and D3) containing all the natural SNPs present. Overall, variant 
lineages are considered to have 1.0 to 10.0% difference in their whole genome (90.0 to 99.0% 
similarity), whereas sub-lineages have 0.5 to 1.0% difference in their whole genome (99.0 to 
99.5% similarity) [Burk et al., 2013]. These differences include SNPs, but can also include indels, 
leading to gaps in alignment and different genome lengths (which is also why reference genomes 
differ slightly over time, as sequencing errors have been identified and corrected). It is worth 
keeping in mind that these reference genomes are useful for researchers as they can be agreed upon 
representatives of a sub-lineage branch based on phylogenetic analysis, but ultimately, they are 
individual isolates of heterogenous groups. There is an ~98% sequence homology between the 
entire HPV16 genomes of the EP reference sequence (sub-lineage A1, GenBank # K02718) and 





Figure 3C.1 – HPV16 A1 vs D3 single-nucleotide polymorphisms (SNPs). The circular genome 
of HPV16 A1 (EP reference sequence, GenBank # K02718) is annotated with genomic features. 
Black lines in the inner ring represent the 151 SNPs present in the D3 variant sub-lineage (AA, 
GenBank # AF402678) throughout the entire genome and present in genes (E6 [7 SNPs], E7 [3], 
E1 [31], E2 and E4 [23], E5 [6], L2 [32], L1 [17]), as well as non-coding regions (short non-coding 




While D2 (Asian-American 2, GenBank # AY686579) and D3 (Asian-American 1, 
GenBank # AF402678) are considered separate sub-lineages, I often refer to them together (i.e., 
D2/D3) as they have identical E6 proteins, with no additional non-synonymous SNP differences 
between their E6 reference sequences. Meanwhile, an additional synonymous SNP is present at 
the gene-level: D2 vs D3 E6 gene (nt 83-559) sequences = 476/477 (99% match). Compared to 
the A1 reference sequence (GenBank # K02718), D2 has six E6 SNPs: G145T, T286A, A289G, 
C335T, T350G, A532G. When comparing D3 to A1, there are seven E6 SNPs (with the additional 
synonymous one underlined): G145T, T286A, A289G, C335T, T350G, G433A, A532G. The three 
non-synonymous SNPs that are shared between D2/D3, relative to the A1 E6 reference sequence, 
lead to amino acid residue changes and potential (albeit subtle) structure differences that could 
have a functional effect [Figure 3C.2]. 
 
Figure 3C.2 – Predicted 3D protein structures for EP (A1, red) and AA (D2/D3, blue). Phyre2 
(intensive mode) [Kelley and Sternberg, 2009; Kelley et al., 2015] was used for in silico prediction 
of the 3D protein structures for EP E6 (GenBank #AAA46939.1) and AA E6 (GenBank 
#AAV91644.1). The sequences were used to generate a 3D model file (.pdb) based on the 151-
residue version of E6, starting at the 2nd Met residue. The 3D models were visualized using PyMOL 
[The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC]. Amino acid residue 
differences numbered based on the 151-residue version of E6 are highlighted in yellow 
(Q14H/H78Y/L83V), causing subtle changes to the protein structure and potential functions. 
83 
 
While D2/D3 E6 proteins may be identical, when considering the full-length genomes there 
are 37 SNPs between D2 and D3 (spanning the entire genome), as well as two indels. To properly 
address our research question, considering the differences between full-length A1, D2, and D3 
HPV16 genomes, we acquired the necessary genomes as plasmids [see APPENDIX A, Table 
A.1]. Generally, the full-length viral genomes were inserted reverse-orientation into LoxP-flanked 
(floxed) multiple-cloning site plasmids also containing a neomycin (G418) resistance gene 
followed by a promoter [as described in CHAPTER 3A; Lee et al., 2004; Wang et al., 2009; 
Bodily et al., 2011]. With this strategy, after Cre-recombination (enabled due to the LoxP sites 
surrounding the viral genome and co-transfection with a Cre-recombinase-expressing plasmid) the 
viral genomes are cut out, recircularized, and have a single LoxP sequence (34 bp long) in a region 
of the viral genome that has been reported not to affect its function (at nt 7,465, the SphI restriction 
site) [Lee et al., 2004]. In addition, the recombination yields a second recircularized plasmid 
containing the remainder of the original plasmid: a neomycin resistance gene (conferring G418 
resistance in mammalian cells), but with the promoter now positioned in front. This design ensures 
that cells transfected with plasmids having been recombined by Cre-recombinase express a 
resistance gene as well as have an intact and active viral episome. While useful, a limitation of the 
Cre-LoxP system which is important to consider for our experiments is that illegitimate DNA 
recombination and damage could occur in cells expressing Cre recombinase, due to cryptic or 
pseudo LoxP sites present within the mammalian genome [Thyagarajan et al., 2000]. 
While working on adapting this design to our HPV16 sub-lineage genomes we considered 
whether the SphI restriction site is the best location for an interruption in the genome. Given that 
the URR has many binding sites for viral as well as host factors, and that there are SNPs in this 
region between EP and AA variants [Hubert et al., 2005], it was possible that the exact site of any 
interruption could have a significant functional effect on the viral life cycle. The final location of 
the LoxP site should be in a non-coding region of the viral genome, with no known function or 
binding sites, and with no sequence variation between EP and AA. The alternative site that we 
selected to compare to the traditional SphI site was the PmlI site [Figure 3C.3]. Given its location 
upstream of major transcription factor binding sites, we hypothesized that the viral life cycle could 
be more productive with this alternative location for a LoxP sequence interruption. On the other 
hand, the PmlI site is located near a late polyadenylation signal/site of the late genes, which could 




Figure 3C.3 – Location of preferred LoxP sites in HPV16’s URR. PmlI and SphI restriction 
sites are shown in the non-coding URR of HPV16’s genomes. Image was constructed using 
Benchling Biology Software. 
 
We had the A1 genome synthesized by GenScript, using the latest version of the A1 
reference sequence available at the time (GenBank # NC_001526.2). We custom ordered three 
plasmids via GenScript’s gene synthesis and cloning service as 4 µg lyophilized DNA: Full 
Length_pcDNA3.1(-), hpv16-ep-sphi-linearized (same site as previous studies, close to E2 binding 
site and within host factor binding sites, start 7,469 - end 7,468, flanked by LoxP sites in the same 
orientation, 8 bp spacer = GCATACAT, to permit excision by Cre recombinase), and hpv16-ep-
pmli-linearized (new site chosen by us, follows the late polyA signal, start 7,270 - end 7,269, 
flanked by LoxP sites in the same orientation, 8 bp spacer = GCATACAT, to permit excision by 
Cre recombinase). Full Length_pcDNA3.1(-) is the non-functional precursor plasmid used to 
construct the two alternate LoxP site placements in the natural EP genome (this was stored at -
20°C as 4 µg lyophilized DNA in the sealed tube as there was no need to transform it into bacteria 
in our hands). The functional plasmids (stored at -20°C until re-suspended) were created via 
mutagenesis from the precursor plasmid to result in a LoxP site at the endogenous viral SphI or 
PmlI restriction site (both contained within the HPV16 URR). These were all cloned into 
pcDNA3.1(-) vectors, containing AmpR (bacterial) and Neo (mammalian) resistance. Target 
sequences were inserted in reverse orientation using XhoI and XbaI to prevent CMV-driven 
expression of viral genes. In silico Cre-lox recombination of these sequences using Cre-
ACEMBLER [Christian Becke and Imre Berger, University of Bristol] resulted in the desired 
products. From Dr. Nagy we requested pCAGGS-NLS-cre to serve as Cre expression plasmid to 
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permit Cre-Lox recombination when co-transfected with floxed plasmids. From Dr. John Lee we 
requested pEGFP Ni HPV16 to use as an HPV16 control for the Cre-Lox system [Lee et al., 2004; 
Bodily et al., 2011]. From Dr. Louise Chow and Dr. Tom Broker we requested pNeo-loxP HPV-
18 to serve as a highly productive positive control for this system in our hands. The HPV18 LoxP 
by the Chow group gives high amplification and viral production in 3D culture [Wang et al., 2009; 
see CHAPTER 3A, Figure 3A.4] whereas Dr. Lee’s HPV16 clone, which contains the W12 
genome, gives low amplification. We suspected originally that the low viral life cycle production 
may be due to the SphI LoxP placement, but using the PmlI site, we found a similar level of capsid 
protein [CHAPTER 3A, Figure 3A.4]. This phenomenon, of HPV16 having low amplification 
and viral life cycle production in vitro compared to HPV18 and HPV31 [personal communication 
with Dr. Bodily], even though HPV16 is the more prevalent type in human cancers, could be a 
topic for future research. 
 Once we confirmed that both synthetic A1 genomes yielded a productive life cycle, and 
that both SphI and PmlI LoxP site placements were feasible (albeit, without substantial 
enhancement in productivity using the alternate PmlI site), we sought full-length D2 and D3 
genomes to incorporate into a Cre-LoxP system. While synthesis was an option, we were able to 
receive D2 and D3 isolate plasmids from Dr. Michael Dean [Appendix A, Table A.1] and instead 
used these to incorporate as floxed inserts into pcDNA3.1(-) vectors, as described in the paragraph 
above. D2 and D3 sequences are currently being sub-cloned by GenScript and will be used in 
future experiments (after being fully sequence verified as well) to rigorously test the variant-
specific integration hypothesis. Addressing the limitations of the epithelial organoid model also 
required enhancements to our strategy for introducing the genomes into host keratinocytes. 
  
3C.2 – Strategies for Introducing HPV16 Genomes to Host Keratinocytes 
Previously, we did not use Cre/LoxP-mediated recombination (as described in the section 
above), but instead our original chemical co-transfection used a re-circularized HPV16 genome, 
along with a GFP selection plasmid, but without any selection gene of its own [Jackson et al., 
2014; 2016]. These experiments were performed in immortalized cells, NIKS [Allen-Hoffman et 
al., 2000], and with this prior technique we would expect at most 50% of the cells after selection 
to contain HPV DNA due to the nature of the co-transfection. We have sought to address the 
limitations of our prior model from the following perspectives: i) cells, ii) plasmids (discussed in 
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3C.1), and iii) transfection technique. First: i) the host cells used should be more biologically 
relevant: mucosal cervical/oral keratinocytes, rather than primary or immortalized foreskin-
derived [non-mucosal] keratinocytes [as previously used in Jackson et al., 2014; 2016]. Next: ii) 
plasmids previously used had only the changes in HPV16 E6 which lead to amino acid changes, 
so full-length variant genomes (A1, D2, D3) should be used. Finally: iii) the overall transfection 
technique required enhancements: the use of Cre-Lox co-transfection based on Dr. Lee (HPV16, 
although they used an adenoviral vector) [Lee et al., 2004] and Dr. Chow (HPV18, but similar 
methods to ours) [Wang et al., 2009], where each requires LoxP sites in the HPV genome in the 
URR. Another aspect of the transfection technique considered was the transfection method, where 
we have tried electroporation in the hopes to improve overall transfection efficiency versus 
chemical transfection efficiency (which is notoriously low in keratinocytes). To achieve efficient 
HPV-DNA transfection, maintenance, and amplification, the full-length HPV16 genomes are 
transfected into monolayer keratinocytes (e.g., previously NIKS and primary human foreskin 
keratinocytes, but more relevant are mucosal keratinocytes: primary oral/gingival keratinocytes or 
primary cervical keratinocytes) employing an approach based on Cre/LoxP-mediated 
recombination [Lee et al., 2004; Wang et al., 2009, Bodily et al., 2011]. Our current strategy [see 
Figure 3A.4 in CHAPTER 3A] involves co-transfection of a floxed viral genome with the Cre-
recombinase expression plasmid. Transfected cells could then be selected (to increase the 
proportion of HPV-containing cells) or expanded and used immediately as the basal keratinocytes 
for generating a multi-layered epithelium.  
From most recent experiments, we noticed that primary cells are more sensitive to HPV 
DNA transfection, yielding higher GFP-positive cells, but with increased cytotoxicity. There is 
also a trade-off between selecting cells and immediately using them for rafts. In terms of our 
research question, the longer we have them in culture the greater the chance of spontaneous 
integration; i.e. selection allows the depletion of the negative cells but with the trade-off that the 
cells are in culture longer, which is especially problematic with primary cells of limited 
proliferative capacity [Villa et al., 2018]. We calculated transfection (electroporation) efficiency 
with a GFP Cre-Lox HPV16 plasmid (control from Dr. Lee) in primary cervical keratinocytes. We 
found the following conditions were optimal for primary cells: 10 µg/mL of DN, 1 x 106 cells per 
cuvette (4 x 105 cells in 400 µL, for each well of a 6-well plate), 100% hypotonic electroporation 
buffer, room temperature, and 1x 100 µs pulse at 280 V. GFP fluorescence images were overlaid 
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with phase-contrast images and GFP signals were only counted in healthy-looking, non-apoptotic 
cells. Smaller, rounded up cells expected to be apoptotic, were not included in our counting. Based 
on these criteria a mean of 6.5% keratinocytes showed GFP expression after 24 hours. After 48 
hours, these numbers increased to a mean ranging from 9.6% (only those strongly expressing GFP) 
to 17.3% (both weakly and strongly expressing GFP). Notably, approximately 50% of the 
electroporated cultures subdued due to cytotoxicity caused by the procedure itself, which could 
not be remedied, e.g., using salmon sperm carrier DNA and/or diluting the plasmid DNA in 
molecular-grade water rather than TE buffer. Hence, these electroporated cultures take four days 
to grow up to ~75% confluence, where they would be used for rafting. We recommend in future 
experiments with adult primary cells to exchange the culture media following attachment of cells 
(to remove hypotonic buffer and decrease toxicity) and to carefully consider selection (and opt not 
to include it) as this may compromise the research question by introducing HPV DNA integration. 
It would also slow down proliferation and take at least twice (or greater) the time to reach the same 
confluence. Altogether, this enhanced procedure based on electroporation is a more gentle and 
straightforward approach with the best possible transfection efficiency (i.e., higher than the <10% 
that we typically obtained in an earlier study) [Jackson et al., 2016] and provides a means to grow 
organoids from mucosal keratinocytes with HPV DNA introduced.  
Improving the full-length viral genomes, the relevance of the host cells, and the transfection 
strategies used for introducing the viral genomes to the host cells are all important factors for 
enhancing our epithelial organoid model to address our research questions. Beyond these 
improvements, future experiments should also assess in situ amplification of HPV DNA as well 
as the replication competence of HPV episomes introduced into host keratinocytes. This can be 
accomplished using DNA qPCR copy number assays and comparing DpnI-treated and untreated 
DNA from experimental cultures [Mori et al., 2014], as DpnI digests bacterially-synthesized 
plasmid DNA. 
 
3C.3 – Adapting the Organoid Model to Study Innate Immunity 
 The next aspect of the organoid epithelial model which we sought to enhance was the 
ability to study innate immunity, specifically to test the hypothesis that HPV16 sub-lineage have 
differential innate immune evasion abilities [Jackson et al., 2014]. A framework for incorporating 
Langerhans cells into the model is discussed in CHAPTER 3A, and our recent progress has 
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revealed that incorporating these cells into the model is challenging. We have optimized cytokine-
induced differentiation of MUTZ-3 cells into Langerhans cells (CD1a+/CD207+, assessed via flow 
cytometry) and have attempted incorporating them into the organoid model. Preliminary 
experiments were performed using magnetic-enrichment to purify the differentiated MUTZ-3 (10-
30% population of CD1a+/CD207+ when unpurified) and seeding different ratios of these cells 
relative to the primary human keratinocytes (2%, a realistic amount found in epithelia, assuming 
all embed vs 20%, 10x greater, in case there is loss) [Figure 3C.4]. While optimal epithelial 
stratification was associated with increased purity and a lower ratio of LCs, as expected, no CD207 
or even CD1a positive cells were detected. Media collections were performed throughout the 
rafting process, followed by membrane washes, and few cells were detected and therefore could 
not account for the undetected cells. It could be possible that the LCs did not survive through the 
2-week rafting period (perhaps due to lack of optimal media and growth factors), or that they are 
very rare and further analysis of serial sections along with optimization of the immunostainings 
will yield their detection. These experiments are currently in progress. Future experiments could 
also include time-course harvests of the rafts [such as described in CHAPTER 3B; Murall et al., 
2019] to check the status of the LCs earlier in the process. 
Finally, beyond incorporating LCs to study innate immunity in the organoid model, it is 
worth emphasizing that innate immunity can be assessed without LCs, using endogenous 
keratinocyte pathways and markers [as discussed in CHAPTER 3A]. For example, keratinocytes 
express a variety of relevant biomarkers that could provide insight on the innate immune 
environment and whether changes due to viral activity could be immuno-evasive (e.g., innate 
sensing molecules such as TLRs, chemokines such as CCL27/28 and IL-18; pro-inflammatory 
cytokine expression such as TNF-α, TGF-β, and type I IFNs; cell-to-cell adhesion molecules, such 
as E-cadherin; and cell-surface receptors such as MHC I/II). An important consideration for future 
experiments, especially for next-generation sequencing, is that the abundance of these keratinocyte 
immune markers may be very low and require sensitive methods (i.e., deeper sequencing, as was 
the case in Jackson et al. [2016], where the average read depth of ~40 million/sample was not 














Figure 3C.4 – Immunocompetent epithelia trials. H&E and immunofluorescence micrographs 
(200X magnification) of five epithelial organoids with differential purity and ratios of Langerhans 
cells to keratinocytes. Blue (DAPI) staining represents nuclei, green (CKs) represents a pan-





CHAPTER 4A – PATHOGEN-HOST ANALYSIS TOOL 
 This chapter was accepted for publication as an applications note in Bioinformatics on 12 
Dec 2018 (DOI: 10.1093/bioinformatics/bty1003) [Gibb et al., 2019], having been originally pre-
printed in bioRxiv on 18 Aug 2017 (DOI: 10.1101/178327). It has been included with permission 
for re-use within this dissertation as per the Oxford University Press (License Number 
4511960249027). While the applications note included below is a brief contribution, the project 
as a whole is more expansive, including GitHub repositories for the software and its 
documentation. 
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4A.1 – Abstract 
4A.1.1 – Summary 
 The Pathogen-Host Analysis Tool (PHAT) is an application for processing and analyzing 
next-generation sequencing (NGS) data as it relates to relationships between pathogens and their 
hosts. Unlike custom scripts and tedious pipeline programming, PHAT provides an integrative 
platform encompassing raw and aligned sequence and reference file input, quality control (QC) 
reporting, alignment and variant calling, linear and circular alignment viewing, and graphical and 
tabular output. This novel tool aims to be user-friendly for life scientists studying diverse 
pathogen–host relationships. 
 
4A.1.2 – Availability and implementation 
 The project is available on GitHub (https://github.com/chgibb/PHAT) and includes 
convenient installers, as well as portable and source versions, for both Windows and Linux 
(Debian and RedHat). Up-to-date documentation for PHAT, including user guides and 
development notes, can be found at https://chgibb.github.io/PHATDocs/. We encourage users and 
developers to provide feedback (error reporting, suggestions and comments). 
 
4A.2 – Introduction 
 Analysis of pathogen data, especially of their genomes [Xiang et al., 2007] via high-
throughput or next-generation sequencing (NGS), is an essential endeavour to understanding 
intricate pathogen–host relationships. While the ease of producing NGS data has grown 
significantly, bottlenecks still exist in its processing and analysis. In particular, short-read 
alignment algorithms and the tools that implement them have matured to the point that they no 
longer represent the major hurdle in the data analysis process [Li and Homer, 2010]. Instead, the 
availability of fast and user-friendly tools has become the limiting factor [Milne et al., 2010]. 
While there are excellent tools which perform one or several discrete functions in the same domain, 
e.g. Bowtie2 [Langmead and Salzberg, 2012] and SAMtools [Li et al., 2009], all-in-one type 
platforms can offer a breadth of features that help address barrier-to-entry (i.e. the ease in which 
users can setup and perform analyses). Integrative multi-tool platforms such as Comparative 
Genomics (CoGe) [Lyons and Freeling, 2008], VirBase [Li et al., 2015], Pathogen-Host 
Interaction Data Integration and Analysis System (PHIDIAS) [Xiang et al., 2007], Galaxy [Afgan 
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et al., 2016] and Unipro UGENE [Okonechnikov et al., 2012] exist, but they are often server or 
cloud-based. The infrastructure behind some of these projects, and their cloud-based nature, 
introduce roadblocks in the transfer of data to and from their servers [Li and Homer, 2010]. One 
solution to such a limitation is to establish an onsite computational cluster. However, technical and 
infrastructure requirements may pose further barrier-to-entry for data analysis. 
We sought to develop the Pathogen-Host Analysis Tool (PHAT) to alleviate these issues 
by presenting an easy-to-setup and easy-to-use platform for life scientists conducting pathogen-
host NGS analysis on common desktop computing hardware and operating systems (e.g. 
Windows). 
 
4A.3 – Features 
Pathogen-host NGS analysis typically begins with high-throughput sequencing output 
files: experimentally relevant nucleic acid read information. PHAT is a platform for analyzing 
these data, with a focus on pathogen sequences within NGS data [Figure 4A.1]. Reads are entered 
into PHAT as FASTQ files [Cock et al., 2010], comprised of sequence reads with per base 
nucleotide identities and quality scores, or pre-aligned SAM/BAM files [Li et al., 2009] generated 
via powerful cloud-based tools such as Galaxy [Afgan et al., 2016]. Quality control can be 
performed on individual files, with graphical reports generated. Reference genomes, recorded as 
FASTA files, must be indexed before they can be visualized or used for analysis. Once a pair of 
forward and reverse reads (paired FASTQ files) and a reference have been input, alignment can 
occur. PHAT also supports unpaired alignment and visualization of pre-aligned sequences. 
The core functions of the PHAT platform as well as FASTQ quality control, sequence 
alignment, visualization, and its automated analyses are performed through well-known, 
established implementations. FastQC (https://www.bioinformatics.babraham. 
ac.uk/projects/fastqc) is used for quality control scoring. Sequence alignment is done by Bowtie2 
[Langmead and Salzberg, 2012] or HISAT2 [Kim et al., 2015], while linear alignment 
visualization is via pileup.js [Vanderkam et al., 2016]. Circular genomes are viewed with our 
enhancements to AngularPlasmid (http://angularplasmid. vixis.com/) which we make available as 
a new project called ngPlasmid (https://github.com/chgibb/ngPlasmid). Automated variant calling 
of single-nucleotide polymorphisms (SNPs) is by VarScan2 [Koboldt et al., 2012]. 
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The graphical user interface, based on GitHub’s Electron project 
(https://electronjs.org/docs), operates in a client-server-based architecture. Each window acts as a 
client, communicating with a background server process. The server manages the saving and 
propagation of workspace data, as well as the generation of additional processes such as sequence 
alignment and quality control. This mechanism allows processes to act as threads, allowing the 
flow of data to and from the application window that invoked it and the created process itself. On 
systems with limited power, the server process limits the number of concurrently running 
processes and the amount of data propagated between windows to reduce memory and central 
processing unit (CPU) usage. We utilize an internal pipeline, spawning new processes as others 
end, passing data from one application window to another (e.g. alignment output). The server 
process, as well as the application windows themselves are implemented in Typescript. These 









Figure 4A.1 – Pathogen-Host Analysis Tool (PHAT) and visualization. The toolbar allows 
input of pathogen-containing NGS data and reference sequences, quality control with FastQC, 
alignment with Bowtie2 or HISAT2, SNP detection with VarScan2, visualization with pileup.js 
and the genome builder, as well as tabular output. Example HPV16 genome maps and coverage 
plots were generated to contrast viral variants: the European Prototype (EP) variant is episomal, 
whereas the Asian-American (AA) variant’s coverage is disrupted by integration into host DNA 





4A.4 – Future Work 
 With the development of PHAT, we aim to bring simple-to-use cross-platform NGS 
analysis to off-the-shelf hardware for life scientists studying pathogen–host relationships. In our 
own lab, we study human papillomavirus type 16 (HPV16) variants and their tumourigenicity in 
epithelia using NGS [Jackson et al., 2016], but PHAT can be applied to a wide variety of pathogen–
host relationships (e.g. genotyping of microbes such as viruses, bacteria, fungi and protozoans) 
from host NGS samples. To aid in our own experimental work, including analysis of HPV 
sequences within curated datasets (e.g. The Cancer Genome Atlas, TCGA), we are currently 
testing a viral-host integration detection feature in PHAT, with linkage to sequence databases. 
Additional features could include advanced alignment options as well as tools for further exploring 
pathogen-host interactions. We plan to actively develop, update and support PHAT based on user 
feedback and needs, with auto-updating features already included, in anticipation of building an 
active user and developer community. 
 
4A.5 – Declarations 
4A.5.1 – Acknowledgements 
 The need for PHAT was conceived by RJ and IZ. Interface was designed by CMG and RJ, 
with programming by CMG. Manuscript writing was carried out by CMG, RJ, SM, JF and IZ. 
Intellectual property considerations made by SM and JF. Thanks to Zehbe Lab members for user 
testing, Dr. M. Togtema for feedback, as well as students M. Pynn, J. Braun, S. Liu, Z. Moorman 
and N. Catanzaro for improvements. We are thankful to the developers of open-source tools that 
are used in PHAT as well as GitHub and Reddit communities for helpful discussions. 
 
4A.5.2 – Funding 
 This work was supported by Natural Sciences and Engineering Research Council of 
Canada (NSERC) grants to IZ (#RGPIN-2015-03855) and RJ (CGS-D #454402-2014). The 
funding body had no role in study design, data collection, data analysis and interpretation, or 




CHAPTER 4B – HPV16 SUB-LINEAGE AND INTEGRATION IN BIG DATA 
This chapter contains an unpublished manuscript in preparation, with additional analyses 
in progress, for pre-print submission to bioRxiv (with the intention to submit for future peer-
review). The purpose of this ongoing bioinformatics study is to further test our hypothesis, using 
large datasets of cancer genome data (along with our experimental work), that the HPV16 D2/D3 
sub-lineage (AA variants) increase the chance (or pattern) of host genome integration compared 
to the A1 sub-lineage (EP variant). 
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4B.1 – Abstract 
Our lab has been intrigued by the fact that viruses often take on the role of mobile elements 
to perpetuate their existence in a complex organism’s genome. Multiple DNA viruses such as 
Epstein-Barr virus, hepatitis B virus, and human papillomavirus (HPV) can invade the human 
genome, as “genomic parasites”. Here we investigate the HPV family which is a widespread group 
of tumour viruses in humans. In our recent in vitro work using 3D organoids, a common variant 
of HPV16’s coding region elicited early integration into the host genome. Next-generation 
sequencing (NGS) data confirmed a phenotype of active proliferation and chromosomal 
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instability—both hallmarks of cancer. Epidemiologically, this variant is associated with a high 
cervical cancer incidence. To substantiate our in vitro data and confirm viral variant-specific 
integration patterns we used bioinformatics analyses of NGS data from population-derived clinical 
samples in The Cancer Genome Atlas (TCGA) curated database. We are particularly interested to 
investigate whether the HPV integration mechanism is sequence-specific (e.g. due to 
microhomologies) or functionally-related (e.g. chromosomal instability, hypomethylation). We 
will align obtained integration data with previously identified integration patterns, conclude with 
an evolutionary perspective on integration mechanisms of mobile elements and highlight the 
clinical utility in developing prognostic personalized biomarkers for cancer treatment efficiency, 
e.g. to detect residual disease. 
 
4B.2 – Introduction 
The co-evolutionary interplay between pathogens and their hosts involves a plethora of 
intriguing biological phenomena, including genomic integration of pathogen DNA into host cells. 
While cellular integration of viral genomic material is a means of propagation for families such as 
Retroviridae (e.g., human immunodeficiency virus, HIV), it can also occur during persistent 
infections with DNA viruses and is often associated with virally-induced cancers. One such family 
of common DNA tumour viruses, Papillomaviridae, is responsible for causing ~5% of all human 
cancers worldwide [Ghittoni et al., 2015]. There are 500+ types of papillomaviruses (PVs) 
discovered to date, including the 83 recently added in Dec 2018 [Pastrana et al., 2018], bringing 
the total to 513 as of Feb 2019 based on the PaVE reference genome database [PaVE: 
https://pave.niaid.nih.gov, Van Doorslaer et al., 2013; 2017b]. The number of non-human PVs 
(currently 183) is also expected to rise using high-throughput genomics [Van Doorslaer and 
Dillner, 2019]. However, most PVs are identified as human papillomaviruses (HPVs) [Van 
Doorslaer et al., 2017a] and these types (330 to date) differ in their propensity for inducing cancer 
as well as their epithelial tropism, with “high-risk” types being the primary cause: predominantly 
via sexually-transmitted persistent HPV type 16 (HPV16) infection of anogenital and 
oropharyngeal mucosa [Ndiaye et al., 2014]. Although HPV16’s genome is small, only ~7.9 kb 
containing nine open reading frames (ORFs) and a variety of alternatively spliced and 
multicistronic variant transcripts [Graham & Faizo, 2017], it encodes potent oncoproteins such as 
E6 and E7 which drive host cells to acquire the hallmarks of cancer [Hanahan and Weinberg, 2000; 
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2011; Mesri et al., 2014]. Their combined actions disable protective apoptotic mechanisms and 
promotes host cell proliferation as outlined by Hoppe-Seyler and colleagues [2018]; a phenomenon 
that could potentially be exploited therapeutically at an RNA [Togtema et al., 2018b] or protein-
level [Togtema et al., 2018a]. This augmented environment can permit chromosomal instability 
and eventual integration of HPV16 sequences into human DNA via double-strand break (DSB) 
repair events [Winder et al., 2007], yielding unique integration signatures found in next-generation 
sequencing (NGS) data from human carcinomas [Holmes et al., 2016]. 
HPV16 sub-lineages (variants) via epidemiological and lab-based studies have been 
reported to infer differing cancer risk [Mirabello et al., 2018 and references within; Clifford et al., 
2019]. HPV16 variant designations were originally based on their geographical region of origin. 
The European “prototype” sub-lineage (EP; A1 according to new nomenclature) was the first 
HPV16 genome published [Seedorf et al., 1985] followed by two additional European (E; A2 and 
A3 according to new nomenclature), one Asian (As; A4 according to new nomenclature), eight 
African (Af-1a, -1b and -2; B1-4 and C1-4 according to new nomenclature), two North-American 
(NA; D1 and D4 according to new nomenclature) and two Asian-American (AA-1 and -2; D3 and 
D2, respectively, according to new nomenclature) [Burk et al., 2013; Mirabello et al., 2018]. 
Recently, we have put our efforts on the variants EP and AA, which differ in only three amino acid 
changes at residues 14 (Q to H), 78 (H to Y) and 83 (L to V) in the major transforming protein E6 
[Richard et al., 2010; Niccoli et al., 2012; Jackson et al., 2014; 2016; Togtema et al., 2015; 
Cuninghame et al., 2017]. Epidemiological studies revealed that the AA sub-lineage infers a higher 
risk factor for dysplasia and an earlier onset of invasive tumours than EP [Xi et al., 1997; Berumen 
et al., 2001]. Our functional assays showed that AAE6 has a greater transforming, migratory, and 
invasive potential than EPE6 when the respective E6 gene was retrovirally transduced into primary 
human keratinocytes in recent long-term in vitro immortalization studies [Richard et al., 2010; 
Niccoli et al., 2012; Togtema et al., 2015]. These observations may be due, at least in part to an 
AAE6-mediated altered, metabolic phenotype reminiscent of the Warburg effect [Richard et al., 
2010; Cuninghame et al., 2017]. Consistent with the hypothesis that AAE6 is more oncogenic than 
EPE6, our recent experimental work revealed that AAE6 in the context of the full-length viral 
genome is more prone to host genome integration than is EPE6 [Jackson et al., 2014; 2016]. 
Another study has mentioned HPV16 sub-lineage and integration, but did not have sufficient 
sample size to address this with respect to the AA sub-lineage (from Jackson et al., 2016): “A 
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previous study of HPV16 integration propensity with respect to the variants did not demonstrate a 
statistically significant difference (P-value = 0.28, two-tailed Fisher’s exact test) between EPE6 (3 
episomal and 20 integrated cases) and the E-T350G variant (6 episomal and 16 integrated cases, 
responsible for one of the residue changes also found in AAE6: L83V) [Xu et al., 2013]. Only one 
tumour sample in their set contained the AA variant, therefore precluding a formal analysis of its 
propensity to integrate, but notably it was in integrated form”. 
To re-conciliate our lab-based finding on integration patterns, we set out to do a search of 
clinical samples with full genome sequence analyses reported on available data bases. Two 
landmark publications of The Cancer Genome Atlas (TCGA) reported on cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC) [TCGA Research Network, 2017] and head 
and neck squamous cell carcinoma (HNSC) [TCGA Research Network, 2015]. More recently, data 
reported by Cantalupo et al. [2018] became available and is of high-interest for our study. Prior to 
the primary TCGA data analysis papers, there was a publication about DNA viruses in TCGA 
RNA-Seq data across a variety of human cancers [Khoury et al., 2013]. Additional literature search 
found several more related papers: HPV and HNSC comprehensive analysis [Castellsagué et al., 
2016] and an HPV16-focused follow-up TCGA-HNSC analysis [Nulton et al., 2017]. Here, they 
report three different groupings of integration status: episomal, integrated, and human-viral 
episomal hybrids, challenging integration data by Parfenov et al. [2014]. The Parfenov et al. study 
disclosed HPV typing and sub-lineage analyses of the 35 HPV+ HNSC cases with 29 containing 
HPV16 of which just one belonging to the AA variant. Interestingly, integration with 16 
breakpoints in the human genome (i.e. ~ 4-fold more than in EP) was reported. In contrast, in the 
Nulton et al. study, for the same case, it was concluded that the human-viral hybrids after initial 
integration were in fact episomal again [Nulton et al., 2017]. Recently, Zapatka et al. [2018] further 
analyzed TCGA data to determine viral associations with cancer, including the impact of 
integrations on host copy number variations. 
Our objective is to data mine TCGA datasets for all HPV16-containing samples, verify 
their sub-lineage genotypes, then characterize their integration status. The most pertinent research 
question for us is whether there are qualitative and quantitative relationships between HPV16 sub-
lineage genotypes and integration status. We hypothesize that HPV16 sub-lineages D2 and D3 
(AA variants) would be more strongly associated with integration than A1 (EP variant), either via 
proportion of episomal vs integrated samples, or more complex characteristics such as total 
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number of integrations (breakpoints) or unique patterns with potential functional relevance. Such 
a finding would confirm our variant-specific integration hypothesis [Jackson et al., 2014; 2016], 
as well as provide a novel mechanism for differing variant tumourigenesis in host tissue. Our 
approach of HPV16 sub-lineage genotyping to detect differential integration patterns correlated to 
A1 and D2/D3 sub-lineages, in a genome-wide analysis, has not been previously addressed. 
  
4B.3 – Methodology 
4B.3.1 – Data acquisition and storage 
Access to controlled sample data from TCGA, using the database of Genotypes and 
Phenotypes (dbGaP), was acquired via application to the electronic Research Administration 
(eRA) commons. We registered our host institution, Lakehead University, as a new organization 
and received a Data Universal Numbering System (DUNS) identifier for access. Our proposal title 
was “Characterization of human papillomavirus type 16 integration sites in cervical and head and 
neck tumour biopsies”, with approval allowing access to TCGA Cervical Squamous Cell 
Carcinoma and Endocervical Adenocarcinoma (TCGA-CESC) as well as Head and Neck 
Squamous Cell Carcinoma (TCGA-HNSC) files for analysis. As the focus of this study was on 
HPV16, only files for TCGA cases that had been previously been marked as HPV16 positive 
[TCGA Research Network, 2015; 2017; Cantalupo et al., 2018] were downloaded. After receiving 
access to the data (which was a lengthy process, with steps outlined in Figure 4B.1), the files were 
stored in an encrypted fashion on a local file server and analyzed on Compute Canada’s Graham 
cluster. Additional work with the data was performed with an in-house server and laptops, all 
password protected and stored securely behind multiple levels of locked doors (as physical 
barriers). See Figure 4B.2 for a graphical summary of our analytical workflow. Additional data 
may be required to further address our research question, such as corresponding RNA-Seq data to 
compare to DNA-Seq (WGS and WXS) data used in our primary analysis, as well as external data 











Figure 4B.1 – Authorized access process for TCGA data. Access to controlled sample genomic 












Figure 4B.2 – Summary of the analytical workflow. First, TCGA high-throughout sequence 
read data (WGS, WXS, or RNA-Seq) is accessed and converted from pre-aligned BAM/SAM 
format to FASTQ read format. This data is then subjected to our HPV16 sub-lineage genotyping 
analysis as well as our HPV16 integration detection analysis, followed by statistical analyses, and 





4B.3.2 – HPV16 sub-lineage genotyping analysis 
The samples chosen for this analysis were those identified as HPV16 positive in the 
landmark TCGA Research Network studies [2015; 2017] as well as Cantalupo et al. [2018]. While 
HPV16-positive cervical cancer (TCGA-CESC) samples had associated sub-lineages already 
identified [TCGA Research Network, 2017], sub-lineage genotyping was not immediately 
available for the head and neck (TCGA-HNSC) cases [TCGA Research Network, 2015]. It was 
thus necessary to develop a pipeline for ascertaining the sub-lineages of unknown identified 
samples (i.e., those that were identified as HPV16 positive by Cantalupo et al., [2018] as well). 
Our pipeline utilized the raw Binary Alignment Map (BAM) files from TCGA. First, Picard’s 
SamToFastq function [http://broadinstitute.github.io/picard/] converted the BAM file to a format 
that could be utilized by HISAT2 [Kim et al., 2015], which then aligned the reads to our HPV16 
A1 reference (GenBank # K02718). Once aligned by HISAT2, SAMtools [Li et al., 2009] was 
used to sort and prepare the file for conversion to mpileup format, which was accomplished using 
SAMtools’ mpileup command. VarScan [Koboldt et al., 2012] was used to extract single 
nucleotide polymorphism (SNP) and indel (insertion and deletion of bases) information from the 
mpileup file, which was then run through a custom R script [4B.8.1 – Supplementary Script 1]. 
The R script altered the reference A1 sequence with the detected SNPs and indels to create a new 
sequence that resembled the true integrated HPV sequence. The final step was to perform a 
multiple sequence alignment (MSA) on the new sequence and references for each sub-lineage of 
HPV16 (A1, A2, A3, A4, B1, B2, B3, B4, C1, C2, C3, C4, D1, D2, D3, D4) using ClustalW 
[McWilliam et al., 2013]. The reference sequences used for each sub-lineage are listed in Table 
4B.1. From Clustal’s Newick tree output, sub-lineages were confirmed visually based on their 
proximity to the sub-lineage references on the phylogenetic tree (example reference tree visualized 
in Figure 4B.3). We are further improving our sub-lineage genotyping pipeline, especially for 
difficult to analyze low-coverage samples (and samples that may contain multiple types of HPV), 
by testing alternative tools such as rkmh [Dawson et al., 2018] and RAxML [Stamatakis, 2014]. 
As well, genotyping could be performed following integration analysis to further verify that 






Table 4B.1 – HPV16 sub-lineage reference genomes used for genotyping. Derived from 
reference data summarized in Burk et al. [2013], Chen et al. [2018a], and Mirabello et al. [2018]. 
 
HPV16 sub-lineage GenBank # Alternate ID Alternative name 
A1 K02718 NC_001526.4 (latest) European Prototype (EP) 
A2 AF536179 w0122 European (E) 
A3 HQ644236 AS411 European (E) 
A4 AF534061 w0724 Asian (As) 
B1 AF536180 w0236 African-1a (Af-1a) 
B2 KU053915 IARC1100085NI African-1 (Af-1) 
B3 HQ644298 Z109 African-1b (Af-1b) 
B4 KU053914 IARC907912AL African-1 (Af-1) 
C1 AF472509 R460 African-2 (Af-2) 
C2 HQ644244 IARC240211GU African-2 (Af-2) 
C3 KU053920 IARC040105BE African-2 (Af-2) 
C4 KU053925 IARC304612MO African-2 (Af-2) 
D1 HQ644257 Qv00512 North-American-1 (NA1) 
D2 AY686579 Qv15321 Asian-American (AA) 2 
D3 AF402678 Qv00995 Asian-American (AA) 1 
D4 KU053931 IARC903812AL North-American-2 (NA2) 
 
 
Figure 4B.3 – HPV16 sub-lineage reference tree for phylogenetic analyses. Branches 



















4B.3.3 – Viral-human integration detection and characterization 
Integration analysis was performed using ViFi [Nguyen et al., 2018] with default settings 
and the included genome references for human (Hg19) and HPV16 A1 (GenBank # K02718). ViFi 
was able to determine viral breakpoints and the number of chimeric reads found in each sample. It 
was difficult to confirm integration status from the ViFi output alone, so to obtain a better 
visualization of the data, our developed Pathogen-Host Analysis Tool (PHAT) [Gibb et al., 2019] 
and a custom R script [4B.8.2 – Supplementary Script 2] were used to create circular visualizations 
of the viral genome and histograms of chimeric reads respectively. Further improvements to our 
integration detection and characterization pipelines are in progress. Full characterization of the 
genomic landscape surrounding detected HPV16 integration sites within human chromosomes will 
be required to comprehensively address our research question, including viral and host nucleotide 
positions, sequence overlap/microhomologies, functional annotations of viral and host features, 
including gene proximity (inside/outside, exon/intron), promoters, enhancers, transcription factor 
binding sites, repeat elements, and proximity to fragile sites. “Virtual ChIP-seq” [Karimzadeh and 
Hoffman, 2018] could be a useful tool to predict nearby transcription factor binding sites (e.g., 
CTCF [Doolittle-Hall et al., 2015; Paris et al., 2015]). As described previously [Jackson et al., 
2016], the region surrounding a viral integration site can be scanned for repeat elements, which 
may be prone to rearrangements, using the UCSC human genome browser RepeatMasker track. 
The current version of the human genome is GRCh38/hg38 (hg19 was GRCh37, and this was 
iterated to “hg38” rather than hg20 to be on par with the GRCh nomenclature, 
https://genome.ucsc.edu/cgi-bin/hgGateway). Another important aspect will be to visualize and 
compare the A1 vs D2/D3 cases; examples exist in the literature [Akagi et al., 2014; Tang et al., 
2013; Holmes et al., 2016; Jackson et al., 2016; Warburton et al., 2018; Lagström et al., 2019]. 
 
4B.3.4 – Statistical analyses 
 Statistical analyses will be performed using the open-source programming language R, 
version 3.5.0 [R Core Team, 2018], within the integrated development environment RStudio, 
version 1.1.453 [RStudio Team, 2015]. Inferences on count data, such as with Χ2 or Fisher’s exact 
tests, will use an a priori significance level of P < 0.05. Beyond these basic statistical analyses, 
future work could explore using deep/machine learning (artificial intelligence-based approaches) 
to aid biological analysis as well as create predictive models [Ching et al., 2018].  
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4B.4 – Preliminary Results 
4B.4.1 – HPV16 sub-lineages in cervical and head and neck cancer datasets 
The number of CESC and HNSC samples that were previously marked as being positive 
for HPV16 differs between studies, likely due to differences in analysis pipelines (e.g., data types 
analyzed, thresholding, and filtering for contamination) [TCGA Research Network, 2017; 
Cantalupo et al., 2018] and poses the major challenge to a valid analysis of sub-lineage association 
with integration. A preliminary sample summary is reported in Table 4B.2 along with a 
preliminary sub-lineage and integration analysis for available CESC sample data in Figure 4B.4. 
Overall, while the proportion of integrated cases was 1.23x higher in D2/D3-containing samples, 
the sample size was very low and this finding was not statistically significant (P = 0.242, Χ2 test). 
To expand upon these preliminary results, we will use our own HPV16 genotyping and sub-lineage 
analyses to verify sub-lineage calls by prior studies, resolve discrepancies, and further analyze the 
“unknown” samples. Based on these prior studies, it is expected that the majority of CESC samples 
are HPV positive, whereas a lower proportion of HNSC samples are HPV positive. While HPV16 
is expected to be the predominant type, we must also consider multi-type infections as well as co-
infections with other pathogens (such as human herpesviruses). As well, cross-contamination 
between samples should be assessed, especially for adjacent cases where sequence libraries could 
be contaminated. From the GDC Data Portal, there are currently 835 relevant CESC and HNSC 
cases for analysis, including 2,568 BAM files (27.84 TB total, average of 33.34 GB/case, including 
all WXS and RNA-Seq sequencing read files and excluding miRNA-Seq files as they are not 
primarily relevant for HPV16 genotyping).There are 307 CESC cases (924 BAM files, 10.44 TB) 
and 528 HNSC cases (1,644 BAM files, 17.41 TB), with both sets including samples from primary 
tumours, metastases, normal blood, and normal solid tissues. Beyond these GDC Data Portal cases 
and files, there appears to be additional files available via the legacy data portal (which includes 
WGS files). Our analysis could also further extend to additional HPV16-positive cancers, such as 
the bladder cancers samples identified by Cantalupo et al. [2018]. As well, additional sample data 






Table 4B.2 – Sample summary breakdown for each TCGA case set. Sample genotypes for 
cancer cases from the Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma 
(CESC) as well as Head and Neck Squamous Cell Carcinoma (HNSC) datasets. CESC HPV16 
data is based on TCGA Research Network [2017] (using the sub-lineages identified at the time, 
which were only 10 of the current 16) and HNSC HPV16 data is based on Parfenov et al. [2014], 
where they performed lineage genotyping (resulting in some sub-lineages being grouped, such as 
A1-A3, as “EUR” genotypes). 
 
Sample genotype CESC (n = 178) HNSC (n = 279) 
Total HPV16 cases  103 (57.9% of CESC cases) 29 (10.4% of HNSC cases) 
A1 70 (68.0% of HPV16 cases) 
22 (75.9% of HPV16 cases) A2 12 (11.7%) 
A3 4 (3.9%) 
A4 4 (3.9%) 2 (6.9%) 
B1 2 (1.9%) 3 (10.3%) 
B2 - - 
C 1 (1.0%) 1 (3.4%) 
D1 - - 
D2 2 (1.9%) - 





Figure 4B.4 – Preliminary analysis of CESC samples. HPV16 sub-lineage (10 of the 16 
considered in TCGA Research Network [2017]) and integration data was analyzed from the CESC 
dataset. While the proportion of integrated samples was 1.23x higher in D2/D3, this finding was 
not statistically significant (P = 0.242, Χ2 test). 
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4B.4.2 – Integration histograms reveal different patterns of integration 
Histograms were created using the integration data for all cases [example shown in Figure 
4B.5]. These histograms provide insight into the integration pattern across chromosomes and 
revealed cases that had clear integration points and others that were more convoluted. Additional 
characterization, both qualitative and quantitative, are required to clarify these patterns and if they 
differ between sub-lineages. To gain additional insight we scanned prior integration data from 
three previous studies, and while these should be mainly assessed in a “qualitative” manner, due 
to sample size restriction, they do not provide evidence against our state hypothesis. The fusion 
transcript for the single AA case in a previous study was revealed to be with ERBB4 near the 
fragile site (FRA) 21 (2q33) with 3Mb distance from the break point [Schmitz et al., 2012]. This 
study used an in-house DNA-Seq approach with DNA fragmentation and adapter targeting 
alongside PCR enrichment of HPV16’s early region and Illumina NGS. Fusion transcripts were 
then confirmed with the APOT assay. The Holmes et al. [2016] study used the Capture-NGS 
approach and describes five integration patterns vs the four patterns in the former study. In the 
Holmes et al., study, they found 33 different SNPs in their pooled sample. Based on these 
signatures 14 SNPs are identical with AA. One SNP was only found in cases with episomal HPV 
but this SNP is not found in the AA. There was no evidence of any of the detected AA SNPs being 
associated with episomal HPV DNA. In fact, one of 33 SNPs was found in cases with 
predominantly episomal HPV (>50%) while 14/33 SNPs are found in cases with <50% episomal 
HPV suggesting that in the Holmes study, there is no evidence to disprove our hypothesis. The 
only HPV16 AA case in the 30 HPV+ head and neck cancers of the TCGA data showed 16 break 
points and was considered integrated in a study by Parfenov et al. but was believed to be episomal 
albeit after initial integration events as shown by Nulton et al. Numerous questions arise from 
these data, such as what would happen to these hybrid HPV DNA “plasmids” containing human 
sequences? Are they replication-competent? How do they impact on HPV evolution? How can 
they form dimers and trimers? This represents a kind of reverse “hijacking” scenario, where HPV 
can pickup pieces of host DNA and incorporate it into its episome. Beside the classical interrupted 
E2 HPV gene, other genes have now also been reported to be interrupted, e.g. E1, E5 and L1 
[Akagi et al., 2013; Warburton et al., 2018]. These findings have implications in how to define 
HPV integration into the human genome, and while breakpoints could possibly arise at any 
location throughout the HPV genomes, particular regions could be more advantageous to viral 
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expression (and ultimately, host cell proliferation, and clonal expansion). Ideally, to classify HPV 
integration events, we will have to analyze both DNA and RNA-Seq data to clarify functional 
effects of DNA integration. 
 
 
Figure 4B.5 – Integration histograms. On the left, a clear case of viral integration, for TCGA-
IR-A3LK (A1 sub-lineage), into human chromosome 10 (supported by > 6000 reads). On the right, 
a “convoluted” integration status for TCGA-IR-A3LL (A2 sub-lineage), into multiple 
chromosomes (158 reads total), with a similar number of reads supporting different chromosomal 
integrations. These could represent true breakpoints or be due to non-specific read alignments. 
 
4B.4.3 – Circular visualizations reveal sequence differences between sub-lineages 
 Using the same set of HPV16-positive samples from the TCGA-CESC dataset, circular 
visualizations were created using PHAT [Figure 4B.6]. A pattern of peaks and valleys is seen in 
each visualization, representing genomic coverage and viral reads corresponding to regions of the 
viral genome. Some valleys were present in all visualizations (at ori, near 4,200 bp and near 6,900 
bp), but two valleys in particular (near 2,300 bp and 5,350 bp) were only found in the D3 cases. 
As expected, these valleys were very close to the breakpoints in simple integration cases from our 
ViFi analysis. A valley is representative of few reads mapping to the reference sequence in an area 
and typically could be associated missing regions due to integration events. However, the valleys 
that were present in all visualizations, and not unique to either A1 or D2/D3 cases, can be attributed 
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to technical artifacts: the ori valley is due to sequence alignment being performed on a linear 
sequence which starts and ends at this location, and when circularized is seen as an artificial gap 
in coverage. Circular visualizations and integration histograms will be used to make conclusions 
regarding integration for each sample. 
 
 
Figure 4B.6 – Circular genome visualizations of HPV16. A1 vs D3 coverage plots were created 
using PHAT [Gibb et al., 2019] and then overlaid to emphasize the consistency of the pattern 
valleys. D3 cases, when overlaid, showed consistent valleys (circled in red) at the 2100 – 2400 bp 
range and the 5300 – 5500 bp range. 
 
4B.4.4 – TCGA data used for functional analysis other than integration 
 Eckardt et al. [2018] mapped a global network of virus-host protein interactions by 
purification of the complete set of HPV proteins in multiple cell lines followed by mass 
spectrometry analysis. Their goal was to determine which HPV-human interactions were most 
directly involved in cancer. They described an integrative strategy combining the complete HPV-
human interactome with the genomic mutational landscape of tumours. Genomic data were 
obtained from 177 CESCs and endocervical adenocarcinomas and 505 HNSCs from the TCGA 
along with 118 HNSC samples from the University of Chicago (http://gdac.broadinstitute.org) 
[Seiwert et al., 2015], yielding a combined cohort of 295 HPV-positive and 505 HPV-negative 
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tumour samples. The genes impacted by either single nucleotide alterations or copy number 
alterations in each sample were determined based on subtractive analysis of paired tumour and 
normal whole-exome sequences or SNP arrays, respectively. This combined proteomic and genetic 
approach provided a systematic means to study the cellular mechanisms hijacked by virally 
induced cancers. Like Eckardt et al. [2018], the Seiwert et al. [2015] study also used the HNSC 
samples from the University of Chicago showing that the mutational makeup of HPV-positive and 
HPV-negative cancers differs. Generally, HNSC harbours multiple therapeutically important 
genetic aberrations, including frequent aberrations in the FGFR and PI3K pathway genes. A 
different database, i.e. from the University of Texas Medical Branch (UTMB Health) in Galveston, 
Texas was used by LeConte et al. [2018] to investigate SNPs in the HPV16 genome and compared 
cervical with head and neck. Notably, no full genome sequence data or information regarding 
population demographics (e.g., ethnicity) were available. This study was an archival tissue cohort 
assessment comprising 226 HNSCs and 154 CESCs formalin-fixed and paraffin-embedded 
samples. Interestingly, compared to the EP sub-lineage, AA was less frequent in HNSC vs CESC. 
 
4B.5 – Discussion 
While presently we have performed literature review, acquired access to relevant TCGA 
data, setup our analysis infrastructure, and carried out preliminary analyses for HPV16 sub-lineage 
genotype and integration, continued efforts are required to comprehensively address our research 
aims. First, what insight do we glean from the sub-lineage genotyping of both head and neck and 
cervical cancer datasets? From initial results, it seems there are only a small number of cases with 
D2/3 (AA) sub-lineage compared to A (European) sub-lineages, which presumably is 
representative of the prevalence of these sub-lineages in the study/sample population. 
Additionally, is there a difference in sub-lineage distribution between head and neck and cervical 
cancer samples, and how do unique anatomical sites factor into the natural history of these viral 
infections, including risk of integration [LeConte et al., 2018; Combes and Franceschi, 2018; 
Eckhardt et al., 2018; Funk et al., 2018]? Next, what insight do we glean from integration analysis 
of both head and neck and cervical cancer datasets, with respect to sub-lineages present? Do we 
reject or fail to reject our hypothesis that D2/D3 is more strongly associated with integration, and 
do we have sufficient statistical power for this conclusion, or is sample size too low? Besides the 
general hypothesis (based on counts/proportion data), are there any differences in integration 
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patterns that are unique? Even with TCGA datasets, a major limitation in answering these 
questions are the small number of D2/D3 samples, and it may be necessary to extend these analyses 
beyond the well-curated TCGA database, but more broadly into other databases (e.g., the SRA). 
While additional samples could possibly be found and incorporated into our analyses, these data 
may lack sufficient metadata to be easily searchable and screened (e.g., experimental vs clinical 
data). As well, since the needs of our specific HPV-based analyses may not have been considered 
a priori when data were collected for those samples, there may be significant variability in data 
formats, read lengths, depths, and quality. Specifically, whether sequence capture or enrichment 
for HPV sequences was performed would greatly affect the probability of detecting HPV 
sequences [Holmes et al., 2016; Jackson et al., 2016]. Additionally, contaminant sequences, such 
as HPV18 sequences from the seemingly ubiquitous HeLa cell line, could be present and require 
filtering [Cantalupo et al., 2015]. It will be important to determine the role of co-infections with 
multiple PV types, as well as other microbes common to the epithelia. Sequencing errors could 
further confound variant identification, requiring careful mitigation [Stewart et al., 2018]. Overall, 
while these challenges exist, potentially relevant datasets deserve analysis and could be useful 
contributions. There have been efforts to curate reference viral databases for helping detect novel 
viruses and aide analysis of high-throughput sequencing data [Goodacre et al., 2018]. As well, 
recent perspectives on optimizing sample preparation, sequencing, and analysis for viral detection 
have been discussed elsewhere [Lambert et al., 2018; Ng et al., 2018; Chen et al., 2018b]. 
Overcoming these challenges can help address the rapidly increasing number of viruses discovered 
via high-throughput sequencing [Tisza et al., 2019] and provide support for the recent call to 
classify viruses [Kuhn et al., 2019]. 
Additional work is also required to determine the factors involved in a HPV16 sub-lineage-
specific genomic instability and integration risk, including the role of defective DNA damage 
repair pathways [Seiwert et al., 2015; Ratnaparkhe et al., 2018], and whether there are also 
connections to altered innate immune pathways [Bakhoum et al., 2018]. It is also worthwhile to 
explore relationships between E6 splice variants and genomic stability [Olmedo-Nieva et al., 
2018]. Researchers continue to explore novel mechanisms surrounding HPV16 integration, such 
as “super-enhancer-like elements” [Warburton et al., 2018] and interruption of tumour suppressor 
genes [Zhao et al., 2016]. Future research could continue exploring these relationships, such as 
determining the role of non-coding genome elements in genomic instability (e.g., lncRNAs) 
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[Munschauer et al., 2018], the similarities of viral-human integration with mobile elements and 
human fusion genes [Imielinski and Ladanyi, 2018], as well as evolutionary perspectives [Petrie 
et al., 2018]. Finally, it remains to be seen how clinically-relevant HPV16 sub-lineage genotyping 
could be, and whether this could lead to improved care and outcome for patients. One strategy 
could be to compute individual risk scores based on the co-factors affecting risk of disease 
progression [Bastarache et al., 2018]. New screening techniques could also be useful, such as urine 
sampling [Van Keer et al., 2018] followed by high-throughput sequencing and HPV genotyping, 
as well as assessing methylation signatures [Cook et al., 2018]. 
 
4B.6 – Conclusion 
From a basic science perspective, analysis of these big data helps us understand more about 
the mechanisms by which pathogens can become integrated into their hosts, akin to mobile 
elements, and by consequence lead to persistence of those sequences as well as disease 
progression. In the case of HPV16, a small number of changes in its genome may be responsible 
for increased host genetic instability and integration propensity. Additional bioinformatics analysis 
of these and other ex vivo data, coupled with in vitro experimental work, is required to further test 
this hypothesis. Hypothesis-free exploration of these data will also be important to clarify the gaps 
in our existing knowledge and identify fascinating phenomena to test in future experiments [Pipas, 
2019]. From an applied science and clinical perspective, HPV16 sub-lineage genotyping can be 
used for preventative screening and routine monitoring, and next-generation sequencing 
specifically could be used on blood to detect integrated HPV sequences in circulating-tumour DNA 
(ctDNA) [Holmes et al., 2016] as a tumour-specific diagnostic biomarker and for monitoring 
residual disease and recurrence after treatments. 
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CHAPTER 5 – CONCLUSIONS 
This dissertation addresses the unique pathogen-host relationship of HPV16 sub-lineages 
by combining novel techniques in human epithelial organoid modelling and “-omics”-based 
bioinformatics analyses. By combining these approaches, I sought to provide additional insight 
into how small changes in this tumourigenic virus could lead to increased risk for cancer 
progression, specifically via genomic instability and host genome integration. Although the HPV 
genome is small, and much about its natural history and molecular interactions within human 
epithelia has been learned in these past decades, there is clearly more to uncover regarding the 
complexity of its interactions and its multipurpose gene products [Mirabello et al., 2018]. While 
exploring this biological theme I also aimed to make original contributions in the field of 
biotechnology, specifically for human epithelial organoids and informatics tools. 
Chapter-specific findings, challenges, and future directions are discussed throughout the 
dissertation, but their significance is summarized here. CHAPTER 2’s significance is primarily 
in the domain of basic natural science, in that we have potentially uncovered a natural phenomenon 
(a human papillomaviral variant with a predisposition for genomic integration under experimental 
conditions) using bio-engineered human tissue. We hypothesize that this integration phenomenon 
is related to an increased cancer risk. This work is impactful due to its collaborative and 
interdisciplinary nature, using innovative technologies such as three-dimensional organotypic 
epithelial cultures, viral sequence-capture, and next-generation sequencing coupled with 
bioinformatics. The use of “-omics” techniques allowed us to gain an understanding of widespread 
changes in the human (and viral) genome and transcriptome. The main limitation of this work is 
that the integration phenomenon may be attributable to artificial experimental conditions (e.g., 
monolayer cell culture transfection and selection of viral genomes prior to rafting; including only 
E6 SNPs and not all those naturally found throughout the entire viral genome), which is why we 
sought to further enhance the model and confirm these findings using clinically-derived data. 
Following the initial findings, the next three chapters focus on our epithelial organoid 
model. CHAPTER 3A is a significant contribution as it provides a historical overview of epithelial 
culturing, our perspectives on experimental designs for studying HPV16 viral life cycle in a natural 
setting, as well discussion on how to include innate immune components for assessing the HPV16 
innate immune evasion hypothesis. As discussed in its chapter, one of the main limitations of 
epithelial organoids is that they are a simplification of the actual tissue complexity and 
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heterogeneity that is present in vivo, lacking other cell types, vasculature, and microbiota. While 
these factors likely play a role in HPV-induced carcinogenesis [Łaniewski et al., 2018], modelling 
them all in vitro becomes a complex task. CHAPTER 3B applies our organoid model to in silico 
applications (i.e., the stratification of epithelia for studying infection dynamics), and represents a 
significant cross-pollination of our efforts with evolutionary ecologists studying infectious 
diseases. This is a timely contribution, as cross-talk between biologists and mathematical 
modellers can lead to improved biological and mathematical models, such as the recent example 
of factors affecting epidermal thickness being used to predict optimal shapes (“sinusoidal 
undulations”, in this case) for epithelial growth [Kumamoto et al., 2018]. CHAPTER 3C is a 
significant work in progress as it chronicles our recent progress and challenges of enhancing the 
epithelial organoid model. A limitation of our controlled experimental approach is that we 
introduce viral genomes into monolayer keratinocytes (which make up the basal layer of 
epithelium at the start of 3D culturing) using either chemical transfection or electroporation, rather 
than a natural infectious process via exposure of viral particles to naïve epithelia. An alternative 
approach could potentially allow us to study factors affecting viral entry and the earliest stages of 
the viral life cycle. As well, a significant challenge encountered when improving the model was 
that introducing immune cells, such as Langerhans cells, can negatively affect stratification (and 
as a result, could impact a viral life cycle). Alternative methods for testing innate immune evasion 
may be necessary (e.g., using a transwell culture assay to investigate the role of LC and assessing 
keratinocyte innate immune markers like TLRs and IFNs) [Jackson et al., 2014]. Future studies 
should also consider taking advantage of time-course experiments as well as single-cell [Lukowski 
et al., 2018] and in situ techniques, as the epithelia organoid is heterogenous due to the various 
cells, stratified layers, and viral activities at different times and spatial locations. 
A computational “-omics” approach, offered by high-throughput sequencing and 
bioinformatics analyses, provides an ideal method for addressing and generating basic research 
questions. However, such analyses require advanced computational skills, which can be a barrier 
to researchers [Blankenberg et al., 2011]. The software described in CHAPTER 4A, Pathogen-
Host Analysis Tool (PHAT), is a significant contribution aimed at reducing this barrier-to-entry. 
This project involved developing custom software, in collaboration with computer scientists, 
allowing for high-throughput data analysis and visualization for biologists without extensive 
computational knowledge. This was accomplished by integrating open-source tools into a user-
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friendly platform. Our intention was to provide a tool with simplified workflows and a means of 
engaging with data, but as a result the main limitations are that the software is not fully 
customizable from a user perspective (e.g., default parameters for alignments) and is not available 
for all possible operating systems and configurations. As well, since new tools frequently emerge 
in the bioinformatics space, it would become an intractable problem to integrate every potentially 
useful tool into PHAT. Researchers comfortable with programming and scripting, either 
standalone or using the cloud, or that have dedicated infrastructure and support for bioinformatics, 
would likely prefer to use their own custom-workflows allowing greater customization, flexibility, 
and access to processing power. To alleviate these concerns, we provide PHAT as an open-source 
project and invite users and developers to provide feedback and further improvements. Beyond 
this informatics tool contribution, CHAPTER 4B contains recent progress in testing our HPV16 
variant-specific integration hypothesis using curated clinical data from TCGA datasets. This work 
is significant as it utilizes our software tool (PHAT) and could provide ex vivo support of our in 
vitro findings, making good use of pre-existing data. The main limitation is the small number of 
D2/D3 sub-lineage samples and that a more comprehensive analysis of their specific integration 
patterns is required for both cervical and head and neck cancer datasets. Beyond these “-omics” 
analyses, computational techniques continue to be utilized for HPV-associated cancers, with a 
recent report on deep learning to detect cervical cancer via image analysis [Hu et al., 2019]. 
There is fundamental scientific value in understanding how subtle changes in a pathogen’s 
genome can lead to host consequences, as is the case with HPVs promoting tumourigenesis within 
human epithelia. Not only does this extend our knowledge of the molecular basis of these 
afflictions (i.e., anogenital and oropharyngeal cancers), and their heterogeneity, but it provides 
fodder for developing biomarkers, diagnostics, prognostics, and therapeutics to relieve disease 
burden and ultimately improve the quality of human life. Furthermore, the resulting 
biotechnologies that are developed, enhanced, and implemented can be extended to study diverse 
pathogen-host relationships (i.e., other oncoviruses and infectious microbes) and used in other 
fields of research. To maximize the benefit of these tools for understanding the variability of 
complex biological systems researchers should continue to integrate biological and computational 
sciences (along with a healthy dose of philosophy [Laplane et al., 2019]), in an open-source and 
accessible manner, to further improve our ability to design meaningful experiments as well as 
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Table A.1 – Plasmid information. Plasmids were either provided as gifts, shared via a material 
transfer agreement (MTA), or custom-ordered. 
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